Document:

<Page>

                                                                    Exhibit 10.6

                               ACTIVBIOTICS, INC.

                        2006 EMPLOYEE STOCK PURCHASE PLAN

     The following constitute the provisions of the 2006 Employee Stock Purchase
Plan of ActivBiotics, Inc.

1.   PURPOSE

     The purpose of the Plan is to provide employees of the Company and its
Designated Subsidiaries with an opportunity to purchase Common Stock of the
Company. It is the intention of the Company to have the Plan qualify as an
"Employee Stock Purchase Plan" under Section 423 of the Code. The provisions of
the Plan shall, accordingly, be construed so as to extend and limit
participation in a manner consistent with the requirements of that section of
the Code.

2.   DEFINITIONS

     2.1. BOARD means the Board of Directors of the Company.

     2.2. CODE means the Internal Revenue Code of 1986, as amended.

     2.3. COMMON STOCK means the common stock, par value $0.01 per share, of
the Company.

     2.4. COMPANY means ActivBiotics, Inc., a Delaware corporation.

     2.5. COMPENSATION means all regular straight time compensation including
commissions but shall not include payments for overtime, shift premium,
incentive compensation, incentive payments, bonuses and other irregular or
infrequent compensation or benefits.

     2.6. CONTINUOUS STATUS AS AN EMPLOYEE means the absence of any interruption
or termination of service as an Employee. Continuous Status as an Employee shall
not be considered interrupted in the case of (i) sick leave; (ii) military
leave; (iii) any other leave of absence approved by the Administrator, provided
that such leave is for a period of not more than 90 days, unless reemployment
upon the expiration of such leave is guaranteed by contract or statute, or
unless provided otherwise pursuant to Company policy adopted from time to time;
or (iv) in the case of transfers between locations of the Company or between the
Company and its Designated Subsidiaries.

     2.7. CONTRIBUTIONS means all amounts credited to the account of a
participant pursuant to the Plan.

     2.8. CORPORATE TRANSACTION means a merger or consolidation of the Company
with and into another person or the sale, transfer, or other disposition of all
or substantially all of the Company's assets to one or more persons (other than
any wholly-owned subsidiary of the Company) in a single transaction or series of
related transactions.

     2.9. DESIGNATED SUBSIDIARIES means the Subsidiaries which have been
designated by the Board from time to time in its sole discretion as eligible to
participate in the Plan.

<Page>

                                        2

     2.10. EMPLOYEE means any person, including an Officer, who is customarily
employed for at least twenty (20) hours per week and more than five (5) months
in a calendar year by the Company or one of its Designated Subsidiaries.

     2.11. EXCHANGE ACT means the Securities Exchange Act of 1934, as amended.

     2.12. OFFERING COMMENCEMENT DATE means the first business day of each
Offering Period of the Plan.

     2.13. OFFERING PERIOD means any of the periods, generally of six (6) months
duration, as set forth in Section 4.

     2.14. OFFICER means a person who is an officer of the Company within the
meaning of Section 16 of the Exchange Act and the rules and regulations
promulgated thereunder.

     2.15. OFFERING TERMINATION DATE means the last business day of each
Offering Period of the Plan.

     2.16. PLAN means this Employee Stock Purchase Plan.

     2.17. PURCHASE PRICE means with respect to an Offering Period an amount
equal to eighty five percent (85%) of the Fair Market Value (as defined in
Section 7.2 below) of a Share on the Offering Commencement Date or on the
Offering Termination Date, whichever is lower; provided, however, that (i) if
there is an increase in the number of Shares available for issuance under the
Plan as a result of a stockholder-approved amendment to the Plan, (ii) all or a
portion of such additional Shares are to be issued with respect to the Offering
Period underway at the time of such increase ("Additional Shares"), and (iii)
the Fair Market Value of a Share of Common Stock on the date of such increase
(the "Approval Date Fair Market Value") is higher than the Fair Market Value on
the Offering Commencement Date for such Offering Period, then in such instance
the Purchase Price with respect to Additional Shares shall be eighty five
percent (85%) of the Approval Date Fair Market Value or the Fair Market Value of
a Share of Common Stock on the Offering Termination Date, whichever is lower.

     2.18. SHARE means a share of Common Stock, as adjusted in accordance with
Section 18 of the Plan.

     2.19. SUBSIDIARY means a corporation, in an unbroken chain of corporations
beginning with the Company if, at the time of the granting of the option, each
of the corporations other than the last corporation in the unbroken chain owns
stock possessing fifty percent (50%) or more of the total combined voting power
of all classes of stock in one of the other corporations in such chain.

3.   ELIGIBILITY

     3.1. Any person who is an Employee as of the Offering Commencement Date of
a given Offering Period shall be eligible to participate in such Offering Period
under the Plan, subject to the requirements of Sections 5.1 and the limitations
imposed by Section 423(b) of the Code.

<Page>

                                        3

     3.2. Any provisions of the Plan to the contrary notwithstanding, no
Employee shall be granted an option under the Plan (i) if, immediately after the
grant, such Employee (taking into account stock which would be attributed to
such Employee pursuant to Section 424(d) of the Code) would own capital stock of
the Company and/or hold outstanding options to purchase stock possessing five
percent (5%) or more of the total combined voting power or value of all classes
of stock of the Company or of any Subsidiary of the Company, or (ii) if such
option would permit his or her rights to purchase stock under all employee stock
purchase plans (described in Section 423 of the Code) of the Company and its
Subsidiaries to accrue at a rate which exceeds Twenty-Five Thousand Dollars
($25,000) of the Fair Market Value (as defined in Section 7.2 below) of such
stock (determined at the time such option is granted) for each calendar year in
which such option is outstanding at any time.

4.   OFFERING PERIODS

     Each Offering Period will begin on January 1 or July 1 and end on the next
following June 30 or December 31, respectively, with the first Offering Period
commencing on January 1, 2007. At any time and from time to time, the Board may
change the duration and/or the frequency of Offering Periods with respect to
future Offering Periods or suspend operation of the Plan with respect to
Offering Periods not yet commenced.

5.   PARTICIPATION

     5.1. An eligible Employee may become a participant in the Plan by
completing a subscription agreement on the form provided by the Company and
filing it with the Company's payroll office prior to the applicable Offering
Commencement Date, unless a later time for filing the subscription agreement is
set by the Board for all eligible Employees with respect to a given Offering
Period. The subscription agreement shall set forth the percentage of the
participant's Compensation (subject to Section 6.1 below) to be paid as
Contributions pursuant to the Plan.

     5.2. Payroll deductions shall commence on the first payroll following the
Offering Commencement Date and shall end on the last payroll paid on or prior to
the Offering Termination Date of the Offering Period to which the subscription
agreement is applicable, unless sooner terminated by the participant as provided
in Section 10.

6.   METHOD OF PAYMENT of CONTRIBUTIONS

     6.1. A participant may elect to have payroll deductions made on each payday
during any Offering Period in an amount not less than one percent (1%) and not
more than fifteen percent (15%) (or such other percentage as the Board may
establish from time to time before an Offering Commencement Date) of such
participant's Compensation on each payday during the Offering Period. All
payroll deductions made by a participant shall be credited to his or her account
under the Plan. A participant may not make any additional payments into such
account.

     6.2. A participant may discontinue his or her participation in the Plan as
provided in Section 10. In addition, if the Board has so announced to Employees
at least five (5) days prior to the scheduled beginning of the next Offering
Period to be affected by the Board's determination, a participant may, on one
occasion only during each Offering Period, change the rate of his or her
Contributions with respect to the Offering Period by completing and filing with
the Company a new subscription agreement authorizing a change in the payroll
deduction rate. If otherwise permitted, no such change shall enable a
participant to resume Contributions other than as of an

<Page>

                                        4

Offering Commencement Date, following a withdrawal of Contributions during an
Offering Period pursuant to Section 10. Any such change in rate shall be
effective as of the first payroll period following the date of filing of the new
subscription agreement, if the agreement is filed at least ten (10) business
days prior to such period and, if not, as of the second following payroll
period.

     6.3. Notwithstanding the foregoing, to the extent necessary to comply with
Section 423(b)(8) of the Code and Section 3.2 herein, a participant's payroll
deductions may be decreased during any Offering Period scheduled to end during
the current calendar year to zero percent (0%). Payroll deductions reduced to
zero percent (0%) in compliance with this Section 6.3 shall re-commence
automatically at the rate provided in such participant's subscription agreement
at the beginning of the first Offering Period which is scheduled to end in the
following calendar year, unless terminated by the participant as provided in
Section 10.

7.   GRANT OF OPTION

     7.1. On the Offering Commencement Date of each Offering Period, each
eligible Employee participating in such Offering Period shall be granted an
option to purchase on the Offering Termination Date of that Offering Period a
number of Shares determined by dividing such Employee's Contributions
accumulated prior to such Offering Termination Date and retained in the
participant's account as of the Offering Termination Date by the applicable
Purchase Price. However, the maximum number of Shares an Employee may
purchase during each Offering Period shall be sixty thousand (60,000) Shares,
and provided further that such purchase shall be subject to the limitations
set forth in Sections 3.2 and 12.

     7.2. The fair market value of the Company's Common Stock on a given date
(the "Fair Market Value") means the value of a share of Common Stock on a
particular date determined by such methods or procedures as may be established
by the Committee. Unless otherwise determined by the Committee, the Fair Market
Value of the Common Stock as of any date (or, in the event that the Common Stock
is not traded on such date, on the immediately preceding trading date), is the
closing price for the Common Stock as reported by the National Association of
Securities Dealers Automated Quotation ("Nasdaq") System (or on any other
national securities exchange on which the Common Stock is then listed) for that
date or, if no closing price is reported for that date, the closing price on the
next preceding date for which a closing price was reported.

8.   EXERCISE OF OPTION

     Unless a participant withdraws from the Plan as provided in Section 10, his
or her option for the purchase of Shares will be exercised automatically on the
Offering Termination Date of an Offering Period, and the maximum number of full
Shares subject to the option will be purchased at the applicable Purchase Price
with the accumulated Contributions in his or her account. No fractional Shares
shall be issued. The Shares purchased upon exercise of an option hereunder shall
be deemed to be transferred to the participant on the Offering Termination Date.
During his or her lifetime, a participant's option to purchase Shares hereunder
is exercisable only by him or her.

<Page>

                                        5

9.   DELIVERY

     As promptly as practicable after each Offering Termination Date of each
Offering Period, the Company shall arrange the delivery to each participant, as
appropriate, of a certificate representing the Shares purchased upon exercise of
his or her option. Any payroll deductions accumulated in a participant's account
which are not sufficient to purchase a full Share shall be retained in the
participant's account for the subsequent Offering Period, subject to earlier
withdrawal by the participant as provided in Section 10 below. Any other amounts
left over in a participant's account after an Offering Termination Date shall be
returned to the participant.

10.  VOLUNTARY WITHDRAWAL; TERMINATION OF EMPLOYMENT

     10.1. A participant may withdraw all but not less than all of the
Contributions credited to his or her account under the Plan at any time prior to
each Offering Termination Date by giving written notice to the Company. All of
the participant's Contributions credited to his or her account will be paid to
him or her promptly after receipt of his or her notice of withdrawal and his or
her option for the current Offering Period will be automatically terminated, and
no further Contributions for the purchase of Shares will be made during the
Offering Period.

     10.2. Upon termination of the participant's Continuous Status as an
Employee prior to the Offering Termination Date of an Offering Period for any
reason, including retirement or death, the Contributions credited to his or her
account will be returned to him or her or, in the case of his or her death, to
the person or persons entitled thereto under Section 14, and his or her option
will be automatically terminated.

     10.3. In the event an Employee fails to remain in Continuous Status as an
Employee of the Company for at least twenty (20) hours per week during the
Offering Period in which the employee is a participant, he or she will be deemed
to have elected to withdraw from the Plan and the Contributions credited to his
or her account will be returned to him or her and his or her option terminated.

     10.4. A participant's withdrawal during an Offering Period will not have
any effect upon his or her eligibility to participate in a succeeding Offering
Period or in any similar plan which may hereafter be adopted by the Company.

11.  INTEREST

     No interest shall accrue on the Contributions of a participant in the Plan.

12.  STOCK

     12.1. Subject to adjustment as provided in Section 18, the maximum
number of Shares which shall be made available for sale under the Plan shall
be two hundred forty thousand (240,000) Shares. If the Board determines
that, on a given Offering Termination Date, the number of shares with respect

<Page>

                                        6

to which options are to be exercised may exceed (i) the number of shares of
Common Stock that were available for sale under the Plan on the Offering
Commencement Date, or (ii) the number of shares available for sale under the
Plan on such Offering Termination Date, the Board may in its sole discretion
provide that the Company shall make a pro rata allocation of the Shares
available for purchase on such Offering Commencement Date or Offering
Termination Date, as applicable, in as uniform a manner as shall be practicable
and as it shall determine in its sole discretion to be equitable among all
participants exercising options to purchase Common Stock on such Offering
Termination Date. The Company may make pro rata allocation of the Shares
available on the Offering Commencement Date of the applicable Offering Period
pursuant to the preceding sentence, notwithstanding any authorization of
additional Shares for issuance under the Plan by the Company's stockholders
subsequent to such Offering Commencement Date.

     12.2. The participant shall have no interest or voting right in Shares
covered by his or her option until such option has been exercised.

     12.3. Shares to be delivered to a participant under the Plan will be
registered in the name of the participant or in the name of the participant and
his or her spouse, as directed by the participant.

13.  ADMINISTRATION

     The Board, or a committee named by the Board, shall supervise and
administer the Plan and shall have full power to adopt, amend and rescind any
rules deemed desirable and appropriate for the administration of the Plan and
not inconsistent with the Plan, to construe and interpret the Plan, and to make
all other determinations necessary or advisable for the administration of the
Plan. The Board's determinations made in good faith on matters referred to in
this Plan shall be final, binding and conclusive on all persons having or
claiming any interest under this Plan.

14.  DESIGNATION OF BENEFICIARY

     14.1. A participant may file a written designation of a beneficiary who is
to receive any Shares and cash, if any, from the participant's account under the
Plan in the event of such participant's death subsequent to the end of an
Offering Period but prior to delivery to him or her of such Shares and cash. Any
such beneficiary shall also be entitled to receive any cash from the
participant's account under the Plan in the event of such participant's death
prior to the Offering Termination Date of an Offering Period.

     14.2. Such designation of beneficiary may be changed by the participant at
any time by written notice. In the event of the death of a participant and in
the absence of a beneficiary validly designated under the Plan who is living at
the time of such participant's death, the Company shall deliver such Shares
and/or cash to the executor or administrator of the estate of the participant,
or if no such executor or administrator has been appointed (to the knowledge of
the Company), the Company, in its discretion, may deliver such Shares and/or
cash to the spouse or to any one or more dependents or relatives of the
participant, or if no spouse, dependent or relative is known to the Company,
then to such other person as the Company may designate.

15.  TRANSFERABILITY OF OPTIONS AND SHARES

     Neither Contributions credited to a participant's account nor any rights
with regard to the exercise of an option or to receive Shares under the Plan may
be assigned, transferred, pledged or

<Page>

                                        7

otherwise disposed of in any way (other than by will, the laws of descent and
distribution, or as provided in Section 14) by the participant. Any such attempt
at assignment, transfer, pledge or other disposition shall be without effect,
except that the Company may treat such act as an election to withdraw funds in
accordance with Section 10. In addition, if the Board has so announced to
Employees at least five (5) days prior to the scheduled beginning of the next
Offering Period to be affected by the Board's determination, any Shares acquired
on the Offering Termination Date of such Offering Period may be subject to
restrictions specified by the Board on the transfer of such Shares. Any
participant selling or transferring any or all of his or her Shares purchased
pursuant to the Plan must provide written notice of such sale or transfer to the
Company within five business days after the date of sale or transfer. Such
notice to the Company shall include the gross sales price, if any, the Offering
Period during which the Shares being sold were purchased by the participant, the
number of Shares being sold or transferred and the date of sale or transfer.

16.  USE OF FUNDS

     All Contributions received or held by the Company under the Plan may be
used by the Company for any corporate purpose, and the Company shall not be
obligated to segregate such Contributions from its other assets.

17.  REPORTS

     Individual accounts will be maintained for each participant in the Plan.
Statements of account will be given to participating Employees at least
annually, which statements will set forth the amounts of Contributions, the per
Share Purchase Price, the number of Shares purchased and the remaining cash
balance, if any.

18.  ADJUSTMENTS UPON CHANGES IN CAPITALIZATION; CORPORATE TRANSACTIONS

     18.1. ADJUSTMENT. Subject to any required action by the stockholders of the
Company, the number of shares covered by each option under the Plan which has
not yet been exercised and the number of Shares which have been authorized for
issuance under the Plan but have not yet been placed under option (collectively,
the "Reserves"), as well as the maximum number of shares of Common Stock which
may be purchased by a participant in an Offering Period, the number of shares of
Common Stock set forth in Section 12.1 above, and the price per Share of Common
Stock covered by each option under the Plan which has not yet been exercised,
shall be proportionately adjusted for any increase or decrease in the number of
the Company's issued Shares resulting from a stock split, reverse stock split,
stock dividend, combination or reclassification of the Common Stock (including
any such change in the number of Shares of Common Stock effected in connection
with a change in domicile of the Company), or any other increase or decrease in
the number of Shares effected without receipt of consideration by the Company;
provided however that conversion of any convertible securities of the Company
shall not be deemed to have been "effected without receipt of consideration."
Such adjustment shall be made by the Board, whose determination in that respect
shall be final, binding and conclusive.

     18.2. CORPORATE TRANSACTIONS. In the event of a dissolution or liquidation
of the Company, the Offering Period then in progress will terminate immediately
prior to the consummation of such action, unless otherwise provided by the
Board. In the event of a Corporate Transaction, each option outstanding under
the Plan shall be assumed or an equivalent option shall be substituted by the
successor corporation or a parent or Subsidiary of such

<Page>

                                        8

successor corporation. In the event that the successor corporation refuses to
assume or substitute for outstanding options, the Offering Period then in
progress shall be shortened and a new Offering Termination Date shall be set
(the "New Offering Termination Date"), as of which date the Offering Period then
in progress will terminate. The New Offering Termination Date shall be on or
before the date of consummation of the transaction and the Board shall notify
each participant in writing, at least ten (10) days prior to the New Offering
Termination Date, that the Offering Termination Date for his or her option has
been changed to the New Offering Termination Date and that his or her option
will be exercised automatically on the New Offering Termination Date, unless
prior to such date he or she has withdrawn from the Offering Period as provided
in Section 10. For purposes of this Section 18, an option granted under the Plan
shall be deemed to be assumed, without limitation, if, at the time of issuance
of the stock or other consideration upon a Corporate Transaction, each holder of
an option under the Plan would be entitled to receive upon exercise of the
option the same number and kind of shares of stock or the same amount of
property, cash or securities as such holder would have been entitled to receive
upon the occurrence of the transaction if the holder had been, immediately prior
to the transaction, the holder of the number of Shares of Common Stock covered
by the option at such time (after giving effect to any adjustments in the number
of Shares covered by the option as provided for in this Section 18); provided
however that if the consideration received in the transaction is not solely
common stock of the successor corporation or its parent (as defined in Section
424(e) of the Code), the Board may, with the consent of the successor
corporation, provide for the consideration to be received upon exercise of the
option to be solely common stock of the successor corporation or its parent
equal in Fair Market Value to the per Share consideration received by holders of
Common Stock in the transaction.

     The Board may, if it so determines in the exercise of its sole discretion,
also make provision for adjusting the Reserves, as well as the price per Share
of Common Stock covered by each outstanding option, in the event that the
Company effects one or more reorganizations, recapitalizations, rights offerings
or other increases or reductions of Shares of its outstanding Common Stock, and
in the event of the Company's being consolidated with or merged into any other
corporation.

19.  AMENDMENT OR TERMINATION

     19.1. The Board may at any time and for any reason terminate or amend the
Plan. Except as provided in Section 18, no termination of the Plan may affect
options previously granted, provided that the Plan or an Offering Period may be
terminated by the Board on an Offering Termination Date or by the Board's
setting a new Offering Termination Date with respect to an Offering Period then
in progress if the Board determines that termination of the Plan and/or the
Offering Period is in the best interests of the Company and its stockholders or
if continuation of the Plan and/or the Offering Period would cause the Company
to incur adverse accounting charges as a result of the Plan. Except as provided
in Section 18 and in this Section 19, no amendment to the Plan shall make any
change in any option previously granted which adversely affects the rights of
any participant.

     19.2. In addition to the foregoing, without stockholder consent and without
regard to whether any participant rights may be considered to have been
adversely affected, the Board (or its committee) shall be entitled to change the
Offering Periods, limit the frequency and/or number of changes in the amount
withheld during an Offering Period, establish the exchange ratio applicable to
amounts withheld in a currency other than U.S. dollars, permit payroll
withholding in excess of the amount designated by a participant in order to
adjust for delays or mistakes in the

<Page>

                                        9

Company's processing of properly completed withholding elections, establish
reasonable waiting and adjustment periods and/or accounting and crediting
procedures to ensure that amounts applied toward the purchase of Common Stock
for each participant properly correspond with amounts withheld from the
participant's Compensation, and establish such other limitations or procedures
as the Board (or its committee) determines in its sole discretion advisable
which are consistent with the Plan.

20.  NOTICES

     Any notice, demand, request or other communication hereunder to any party
shall be deemed to be sufficient if contained in a written instrument delivered
in person or duly sent by first class registered, certified or overnight mail,
postage prepaid, or telecopied with a confirmation copy by regular, certified or
overnight mail, addressed or telecopied, as the ease may be, (i) if to the
recipient of an Award, at his or her residence address last filed with the
Company and (ii) if to the Company, at its principal place of business,
addressed to the attention of its Chief Executive Officer, or to such other
address or telecopier number, as the case may be, as the addressee may have
designated by notice to the addressor. All such notices, requests, demands and
other communications shall be deemed to have been received: (i) in the case of
personal delivery, on the date of such delivery; (ii) in the case of mailing,
when received by the addressee; and (iii) in the case of facsimile transmission,
when confirmed by facsimile machine report connection with the Plan shall be
deemed to have been duly given when received in the form specified by the
Company at the location, or by the person, designated by the Company for the
receipt thereof.

21.  CONDITIONS TO ISSUANCE OF SHARES

     Shares shall not be issued with respect to an option unless the exercise of
such option and the issuance and delivery of such Shares pursuant thereto shall
comply with all applicable provisions of law, domestic or foreign, including,
without limitation, the Securities Act of 1933, as amended, the Exchange Act,
the rules and regulations promulgated thereunder, applicable state securities
laws and the requirements of any stock exchange upon which the Shares may then
be listed, and shall be further subject to the approval of counsel for the
Company with respect to such compliance.

     As a condition to the exercise of an option, the Company may require the
person exercising such option to represent and warrant at the time of any such
exercise that the Shares are being purchased only for investment and without any
present intention to sell or distribute such Shares if, in the opinion of
counsel for the Company, such a representation is required by any of the
aforementioned applicable provisions of law.

22.  TERM OF PLAN; EFFECTIVE DATE

     The Plan shall become effective upon the IPO Date. It shall continue in
effect for a term of five (5) years unless sooner terminated under Section 19.

<Page>

                                                  FORM OF SUBSCRIPTION AGREEMENT

                               ACTIVBIOTICS, INC.

                        2006 EMPLOYEE STOCK PURCHASE PLAN

                             SUBSCRIPTION AGREEMENT

New Election: ___

Change of Election: ___

     1. I, ________________, hereby elect to participate in the ActivBiotics,
Inc. 2006 Employee Stock Purchase Plan (as amended, the "Plan") for the Offering
Period _____________ ___, _____ to ___________ _____, _____, and subscribe to
purchase shares of the Company's Common Stock in accordance with this
Subscription Agreement and the Plan.

     2. I elect to have Contributions in the amount of ___% of my Compensation,
as those terms are defined in the Plan, applied to this purchase. I understand
that this amount must not be less than 1% and not more than 15% of my
Compensation during the Offering Period. (Please note that no fractional
percentages are permitted).

     3. I hereby authorize payroll deductions from each paycheck during the
Offering Period at the rate stated in Item 2 of this Subscription Agreement. I
understand that all payroll deductions made by me shall be credited to my
account under the Plan and that I may not make any additional payments into such
account. I understand that all payments made by me shall be accumulated, without
interest or earnings, for the purchase of shares of Common Stock at the
applicable purchase price determined in accordance with the Plan. I further
understand that, except as otherwise set forth in the Plan, shares will be
purchased for me automatically on the Offering Termination Date of each Offering
Period unless I otherwise withdraw from the Plan by giving written notice to the
Company for such purpose.

     4. I understand that I may discontinue at any time prior to the Offering
Termination Date my participation in the Plan as provided in Section 10 of the
Plan. I acknowledge that, unless I discontinue my participation in the Plan as
provided in Section 10 of the Plan, my election will continue to be effective
for each successive Offering Period.

     5. I have received a copy of the complete ActivBiotics, Inc. 2006 Employee
Stock Purchase Plan. I understand that my participation in the Plan is in all
respects subject to the terms of the Plan.

     6. Shares purchased for me under the Plan should be issued in the name(s)
of (name of employee or employee and spouse only):

                     _____________________________________

                     _____________________________________

     7. In the event of my death, I hereby designate the following as my
beneficiary(ies) to receive all payments and shares due to me under the Plan:

<Page>

                                        2

NAME: (Please print)                    ________________________________________
                                        (First)         (Middle)          (Last)

_____________________________________   ________________________________________
(Relationship)                          (Address)

                                        ________________________________________

     8. I understand that if I dispose of any shares received by me pursuant to
the Plan within 2 years after the Offering Commencement Date (the first day of
the Offering Period during which I purchased such shares) or within 1 year after
the Offering Termination Date, I will be treated for federal income tax purposes
as having received ordinary compensation income at the time of such disposition
in an amount equal to the excess of the fair market value of the shares on the
Offering Termination Date over the price which I paid for the shares, regardless
of whether I disposed of the shares at a price less than their fair market value
at the Offering Termination Date. The remainder of the gain or loss, if any,
recognized on such disposition will be treated as capital gain or loss.

     I hereby agree to notify the Company in writing within 30 days after the
date of any such disposition, and I will make adequate provision for federal,
state or other tax withholding obligations, if any, which arise upon the
disposition of the Common Stock. The Company may, but will not be obligated to,
withhold from my compensation the amount necessary to meet any applicable
withholding obligation including any withholding necessary to make available to
the Company any tax deductions or benefits attributable to the sale or early
disposition of Common Stock by me.

     9. If I dispose of such shares at any time after expiration of the 2-year
and 1-year holding periods, I understand that I will be treated for federal
income tax purposes as having received compensation income only to the extent of
an amount equal to the lesser of (1) the excess of the fair market value of the
shares at the time of such disposition over the purchase price which I paid for
the shares under the option, or (2) 15% of the fair market value of the shares
on the Offering Commencement Date. The remainder of the gain or loss, if any,
recognized on such disposition will be treated as capital gain or loss.

     I understand that this tax summary is only a summary and is subject to
change. I further understand that I should consult a tax advisor concerning
certain tax implications of the purchase and sale of stock under the Plan.

     10. I hereby agree to be bound by the terms of the Plan. The effectiveness
of this Subscription Agreement is dependent upon my eligibility to participate
in the Plan.

                                        SIGNATURE:
                                                   -----------------------------

                                        SOCIAL SECURITY #:
                                                           ---------------------

                                        DATE:
                                              ----------------------------------

<Page>

                                                    FORM OF NOTICE OF WITHDRAWAL

                               ACTIVBIOTICS, INC.

                        2006 EMPLOYEE STOCK PURCHASE PLAN

                              NOTICE OF WITHDRAWAL

     I, ____________, hereby elect to withdraw my participation in the
ActivBiotics, Inc. 2006 Employee Stock Purchase Plan (the "Plan") for the
Offering Period that began on ________________, _________. This withdrawal
covers all Contributions credited to my account and is effective on the date
designated below.

     I understand that all Contributions credited to my account will be paid to
me within ten (10) business days of receipt by the Company of this Notice of
Withdrawal and that my option for the current period will automatically
terminate, and that no further Contributions for the purchase of shares can be
made by me during the Offering Period.

     The undersigned further understands and agrees that be or she shall be
eligible to participate in succeeding Offering Periods only by delivering to the
Company a new Subscription Agreement.

Dated:
       ------------------------------   ----------------------------------------
                                                  Signature of Employee

                                        ----------------------------------------
                                                 Social Security Number<Page>

                                                                    Exhibit 10.8

                      "CONFIDENTIAL TREATMENT REQUESTED BY
                              ACTIVBIOTICS, INC."

                            CONFIDENTIAL INFORMATION

                           EXCLUSIVE LICENSE AGREEMENT
                                     BETWEEN
                               ACTIVBIOTICS, INC.
                                       AND
                            UNIVERSITY OF WASHINGTON

THIS EXCLUSIVE LICENSE AGREEMENT ("Agreement") is entered into on May 16, 2003
("Effective Date") by and between ActivBiotics, Inc, a Delaware corporation with
its principal place of business at 128 Spring Street, Lexington, MA ("Licensee")
and the University of Washington, a public institution of higher education and
an agency of the state of Washington, acting through its Office of Technology
Licensing ("OTL"), with administrative offices at 4311 11th Avenue NE, Suite
500, Seattle, WA 98105 ("University") (individually the "Party" or collectively
the "Parties").

                                    RECITALS

Whereas, University has developed and owns or is in possession of certain
technology relating to diagnosis and treatment of arterial chlamydial granuloma,
described in OTL# 1168-1291129DL ("UW Technology" as defined below) and
developed by Dr(s) Cho Cho Kuo, Allan Shor, Dorothy L. Patton, Lee Ann Campbell
and J Thomas Grayston;

Whereas, University and Licensee entered into an Exclusive Option Agreement
dated June 13, 2002 ("Exclusive Option Agreement Between ActivBiotics, Inc. and
the University of Washington" attached hereto as Exhibit A and incorporated
herein by reference), which remains in full force and effect;

Whereas, University desires that UW Technology be used as broadly and as soon as
possible in the public interest, and to this end desires to exclusively license
UW Technology to a company capable of commercially exploiting UW Patent Rights
(as defined below);

Whereas, Licensee wishes to obtain a license to UW Patent Rights and Licensee is
under no contractual or other obligation which encumber, restrict, or limit any
of the rights granted by University under this Agreement, and is committed to
commercially exploiting UW Patent Rights; and

Whereas, University is willing to grant such a license to Licensee in order that
Licensed Product(s) (as defined below) be made available on the commercial
market.

Now Therefore, in consideration of the mutual promises set forth herein, and
other good and valuable consideration, the receipt and sufficiency of which is
hereby expressly acknowledged, the Parties hereto, intending to be legally
bound, hereby agree as follows:

1.0 DEFINITIONS

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       1

<Page>

                            CONFIDENTIAL INFORMATION

1.1 All capitalized terms used in this Agreement have the respective meanings
ascribed to them in this Agreement and, unless indicated otherwise, are intended
to include all derivative forms of the terms.

1.2 "Affiliate" means any entity that directly or indirectly controls, is
controlled by, or is under common control with Licensee. For the purposes of
this Paragraph 1.2 "control" means either the right to exercise more than 50% of
the voting rights of an entity, including but not limited to, a controlled
corporation or limited liability company or the power to direct or cause the
direction of the management or policies of any other controlled entity.
Affiliates shall mean only those companies listed on Exhibit 1.2, attached
hereto and incorporated herein by reference, which may be amended from time to
time only with prior written consent of an authorized representative of the
University.

1.3 "Combination Product" shall mean any subject matter sold at a single price,
including but not limited to, products and processes, containing both a
component that constitutes a Licensed Product and one or more other active
components that do not constitute Licensed Product.

1.4 "Confidential Information" means any information and materials of the
University (biological, chemical, or otherwise) not generally known to the
public. Confidential Information may be conveyed in written, graphic, oral,
physical, or electronic form. Confidential Information shall include, without
limitation, UW Technology Rights. Notwithstanding the foregoing, Licensee shall
have no obligation of confidentiality relating to:

     1.4.1 any information of the University that is required to be disclosed by
     judicial or legislative action or government regulation;

     1.4.2 any information that is or becomes part of the public domain through
     no fault of Licensee;

     1.4.3 any information that is known to Licensee prior to the disclosure by
     University, as evidenced by documentation;

     1.4.4 any information that is publicly released as authorized under this
     Agreement by University, its employees or agents;

     1.4.5 any information that is subsequently obtained by Licensee from a duly
     authorized Third Party; or

     1.4.6 any information that is independently developed by Licensee without
     reliance on any portion of the Confidential Information received from
     University and without any breach of this Agreement as evidenced by
     documentation.

1.5 "Field of Use" means diagnosis and treatment of arterial chlamydial
granuloma, which includes related arterial and coronary diseases or disorders
caused by or influenced by arterial chlamydia granuloma lesions and infections.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        2

<Page>

1.6 "Licensed Product" means a product or service, including but not limited to
products, services and processes, which are covered within UW Patent Rights
and/or UW Technology Rights.

1.7 "Licensed Territory" means worldwide.

1.8 "Net Sales" means the gross billed or invoiced amounts for Licensed
Product(s) or Combination Product(s) less discounts and allowances given and
actually taken and which are customary in Licensee's trade, other than those
which permit a reduction in payment by the customer in exchange for early
payment. Notwithstanding the foregoing, Net Sales will not be less than [***]%
of gross billed or invoiced amounts. In the event that Licensed Product(s) or
Combination Product(s) are sold to an Affiliate, then Net Sales shall be the
price which would have been charged if the Licensed Product(s) or Combination
Product(s) in question had been sold on normal terms and conditions to a
purchaser dealing at arm's length with Licensee. Licensed Product(s) and/or
Combination Product(s) shall be deemed "sold" when billed or invoiced, whichever
occurs first.

1.9 "Semi-Annual Period" means a period of six consecutive calendar months
beginning on the first day of either January or July.

1.10 "Sublicense" means the present, future or contingent transfer by Licensee
to a Third Party of any license, right, option, first right to negotiate or
other right granted under the UW Patent Rights and/or UW Technology Rights, in
whole or in part. Sublicense shall include, without limitation, such transfer to
strategic partners and marketing collaborators.

1.11 "Sublicensee" means a Third Party holding a Sublicense under the UW Patent
Rights and/or UW Technology Rights.

1.12 "Sublicensing Fee" means any license fee or non-royalty consideration,
including equity, received by Licensee from a Sublicensee for the grant of a
license to make, have made, use or distribute Licensed Products or Combination
Products and that is not included in Net Sales.

1.13 "Sublicensing Consideration" means cash or non-cash consideration of any
kind received by Licensee or Affiliate from a Sublicensee(s) for the grant of a
Sublicense under this Agreement, including, but not limited to, upfront fees or
milestone fees and including any premium paid by the Sublicensee(s) over Fair
Market Value (hereinafter defined) for stock of the Licensee or an Affiliate in
consideration for such Sublicense. However, not included in such Sublicensing
Consideration are amounts paid to the Licensee or an Affiliate by the
Sublicensee(s) for earned royalties on Licensed Product(s), product development,
research work, clinical studies, and regulatory approvals performed by or for
the Licensee or Affiliate, or third parties on their behalf pursuant to a
specific agreement including a performance plan and commensurate budget "Fair
Market Value" means the average price that the stock in question is publicly
trading at for twenty (20) days prior to the announcement of its purchase by the
Sublicensee(s), or, if the stock is not publicly traded, the value of such stock
as determined by the most recent private financing through a financial investor
(an entity whose sole interest in the Licensee or Affiliate is financial) of the
Licensee or Affiliate that issue the shares

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        3

<Page>

1.14 "Technical Information" means any technical facts, data, or advice, oral or
written (in the form of information contained in patents and patent
applications, reports, letters, drawings, specifications, testing procedures,
training and operational manuals, bills of materials, photographs and related
materials), and/or any tangible material(s), not covered by but reasonably
necessary for practicing UW Patent Rights and developed by UW Researchers before
the Effective Date which is owned by and in possession of University and is not
covered by Third Party rights that would prevent delivery to Licensee.

1.15 "Third Party" means all individuals or entities other than University,
Licensee and Affiliates.

1.16 "UW Researchers" means Dr(s) Cho Cho Kuo, Allan Shor, Dorothy L Patton, Lee
Ann Campbell and J. Thomas Grayston.

1.17 "UW Patent Rights" shall mean the United States issued patents, United
States or international patent application(s) listed in Exhibit 1.16 and any
corresponding patent issued therefrom, including all reissues, divisionals,
continuations, reexaminations and extensions thereof, together with all
corresponding foreign patents, extensions, supplemental protection certificates
and applications corresponding thereto now issued or issued during the term of
this Agreement and which directly relate to UW Technology. Continuations-in-Part
("CIP") Patent Applications will be included with UW Patent Rights only if
Licensee substantially funds the research that results in the filing of a CIP. A
patent or patent application shall cease to be a UW Patent Right when any of the
following occur: a) it expires; b) it is abandoned; or c) it is held to be
invalid or unenforceable by a court of competent jurisdiction from which no
appeal can be taken.

1.18 "UW Technology" means the technology as developed in the University
laboratories of UW Researchers and as described in OTL File # 1168-1291129DL.

1.19 "UW Technology Rights" means UW Technology and Technical Information all of
which is the proprietary information of the University.

2.0 GRANT OF RIGHTS

2.1 Grant. Subject to Licensee's fulfillment of its obligations under this
Agreement, University hereby grants to Licensee an exclusive, royalty-bearing
license, with the right to Sublicense as further set forth in Article 3.0
(Sublicensing), under the UW Patent Rights and/or UW Technology Rights to
import, make, have made, use, sell, offer for sale and have sold Licensed
Product(s) and Combination Product(s) in the Licensed Territory in the Field of
Use.

2.2 University Reserved Rights. The license granted above is subject to a
reserved non exclusive license by University to make, have made, and use
products, processes, or other subject matter covered by the UW Patent Rights
and/or the UW Technology Rights for research, instructional, and/or other
academic purposes University has the right to use the UW Patent Rights and/or UW
Technology Rights for its own sponsored and collaborative research during the
term of this Agreement and to grant material transfer agreements to Third Party
non-profit

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        4

<Page>

entities. University also has the right to publish any information included in
the UW Patent Rights and/or UW Technology Rights or any information that may
result from University's research in this area.

2.3 Federal Government Rights. Licensee acknowledges and understands that UW
Patent Rights may be the result of federal research funding and that such
funding imposes certain obligations on the University. Actions taken by
University to fulfill such obligations shall not be deemed inconsistent with
University's obligations under this Agreement. Licensee acknowledges that such
obligations under federal law include, without limitation, the following: a)
University's granting of a worldwide, non-exclusive, royalty-free license under
any UW Patent Rights by University to the United States government; and b) a
requirement that all United States patents and patent applications within the UW
Patent Rights include a statement of United States government patent rights.
Licensee acknowledges that any and all determinations of federal funding shall
be made solely by University and University's reasonable determination shall be
honored by Licensee. Licensee further acknowledges and agrees that, pursuant to
35 USC 200, the University's grant of an exclusive license to use or sell UW
Patent Rights in the United States are contingent on Licensee's agreement that
any products embodying UW Patent Rights or produced through the use of UW Patent
Rights must be manufactured substantially in the United States, unless Licensee
obtains a waiver from the appropriate federal agency.

3.0 SUBLICENSING

3.1 Right to Sublicense. During the term of this Agreement, Licensee shall have
the right to grant non-exclusive and exclusive Sublicenses to UW Patent Rights
and/or UW Technology Rights within the Field of Use and within the Licensed
Territory at royalty rates and with terms and conditions not less favorable to
University than those required of Licensee by this Agreement.

3.2 Sublicense Subject to this Agreement. Any and all proposed Sublicenses in
and to UW Patent Rights and/or UW Technology Rights granted by Licensee shall be
subject to prior approval of University, which shall not be unreasonably denied,
and shall be subject to the terms of this Agreement.

3.3 Copies to University. Licensee shall give the University written
notification and copies of any Sublicense it may grant under this Article 3.0.
Licensee agrees to provide such written notification indicating the effective
date of execution, effective period and operative provisions, within thirty (30)
days of its execution.. Such documents shall be held in confidence by the
University to the extent permitted by law or regulation.

3.4 Licensee agrees to consider in good faith any potential sublicensees that
University may suggest or recommend.

4.0 DELIVERY OF INFORMATION

4.1 UW Patent Rights. University agrees to disclose to Licensee copies of all
existing patents and patent applications comprising UW Patent Rights and
University shall continue

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        5

<Page>

throughout the term of this Agreement to keep Licensee informed of all material
patent decisions and of all other patents and patent applications, pursuant to
Paragraph 9.1, that may later fall within the scope of UW Patent Rights.

4.2 Technical Information. University agrees to disclose to Licensee any
Technical Information that is in University's judgment reasonably necessary or
valuable to the commercial exploitation of the UW Patent Rights.

5.0 CONFIDENTIALITY

5.1 Confidentiality. Beginning on the Effective Date and continuing throughout
the term of this Agreement and thereafter for a period of three (3) years
("Confidentiality Period"), Licensee shall not disclose or otherwise make known
or available to any Third Party or Affiliate any Confidential Information,
without the express prior written consent of University. During the
Confidentiality Period, Licensee shall maintain the UW Patent Rights and UW
Technology Rights in confidence and refrain from disclosing information related
to UW Patent Rights or UW Technology Rights to a Third Party. In no event shall
Licensee incorporate or otherwise use UW Patent Rights or UW Technology Rights
in connection with any patent application filed by or on behalf of the Licensee.
Licensee agrees to restrict the use of UW Patent Rights and UW Technology Rights
exclusively to the terms of this Agreement. Licensee shall utilize reasonable
procedures to safeguard the Confidential Information. Licensee agrees that its
confidentiality obligations apply to Affiliates.

5.2 Public Records Act. The University of Washington is an agency of the state
of Washington and is subject to the Washington Public Records Act, RCW 42.17.250
et seq, and no obligation assumed by University under this Agreement shall be
deemed to be inconsistent with University's obligations defined under RCW 42.17.
In the event University receives a request for public records under the Public
Records Act for documents containing Confidential Information, and if University
concludes that the documents are not otherwise exempt from public disclosure,
University will provide Licensee notice of the request before releasing such
documents. Such notice shall be provided in a timely manner to afford Licensee
sufficient time to review such documents and/or seek a protective order, at
Licensee's expense. The responsibility for(1) protecting the Confidential
Information shall reside exclusively with Licensee utilizing the procedures
described in RCW 42.17.330.

6.0 DILIGENCE AND DEVELOPMENT MILESTONES

6.1 Development and Commercialization. During the term of this Agreement,
Licensee shall use, and shall compel its Sublicensee to use, at least the same
level of effort and diligence as Licensee uses or has used in proceeding with
its own product development, testing, manufacturing, sales and, where
applicable, initiating clinical trials and obtaining regulatory approval to
develop and commercialize at least one Licensed Product(s) or Combination
Product(s) Specifically, Licensee shall use such level of effort and diligence
in:

     6.1.1 developing Licensed Product(s) or Combination Product(s);

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        6

<Page>

     6.1.2 filing for or seeking regulatory approvals in accordance with the
     business plan; and

     6.1.3 marketing and selling Licensed Product(s) or Combination Product(s)

6.2 Milestones. With regard to each of the Licensed Product(s) or Combination
Product(s), Licensee shall use at least the same level of effort and diligence
as Licensee uses or has used in proceeding with its own product development,
testing, manufacturing, sales and, where applicable, initiating clinical trials
and obtaining regulatory approval to meet all of the following diligence
milestones. Licensee agrees to provide, upon University's request, tangible
evidence of achieving the milestones.

     6.2.1 Assemble a scientific committee containing a multidisciplinary group
     of scientists (including, but not limited to, pathologists, microbiologists
     and cardiologists) for the design and oversight of a study that
     demonstrates the effective use of an antibacterial drug for the therapy of
     arterial chlamydia granuloma ("Study") by July 1st 2004.

     6.2.2 Initiate Study by September 30, 2004.

     6.2.3 Prepare and send to UW Researchers for review a pre-submission
     manuscript prepared by Licensee describing the outcomes of Study by
     December 31, 2005.

     6.2.4 First publication by Licensee or others in a peer reviewed
     international journal of Study by June 31, 2007.

     6.2.5 First publication by Licensee or others in a peer reviewed
     international journal of a study that demonstrates the effective use of an
     antibacterial drug for the therapy of acute or chronic coronary arterial
     chlamydia granuloma by December 31, 2009.

     6.2.6 First publication by Licensee or others in a peer reviewed
     international journal of a study conducted by a multidisciplinary group of
     scientists (including, but not limited to, pathologists, microbiologists
     and cardiologists) establishing that atherosclerosis is an arterial
     chlamydia granuloma or that chlamydia granuloma of the arteries is
     associated pathologically with atherosclerosis by December 31, 2006;

     6.2.7 Execute a strategic partnership and/or a Sublicense agreement for the
     development of Licensed Product(s) or Combination Product(s) with a Third
     Party by December 31, 2008.

     6.2.8 Filing by Licensee or Sublicensee of an NDA with the U.S. Food and
     Drug Administration for the use of antibacterial drugs to treat
     atherosclerosis and/or Chlamydia granuloma by December 31, 2010.

     6.2.9 Licensee or Sublicensee to apply for regulatory approval for Licensed
     Product(s) or Combination Product(s) from the U.S. Food and Drug
     Administration or a foreign equivalent governmental authority by December
     31, 2011.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        7

<Page>

     6.2.10 Licensee or Sublicensee to receive regulatory approval from the U.S.
     Food and Drug Administration or foreign equivalent governmental authorities
     for Licensed Product(s) or Combination Product(s) by December 31, 2012.

6.3 Milestone Payments. Licensee shall pay to University the following
non-creditable, non-cumulative, non-refundable fees within thirty (30) days of
the following milestones:

     6.3.1 [***] dollars ($[***] US) upon the second publication by Licensee or
     others in a peer reviewed international journal of a study establishing
     that atherosclerosis is an arterial Chlamydia granuloma and/or that
     Chlamydia granuloma of the arteries is the constant lesion associated
     pathologically with atherosclerosis;

     6.3.2 [***] dollars ($[***] US) upon Licensee's execution of a strategic
     partnership agreement and/or a Sublicense agreement for the development of
     antibacterial drugs for use in Chlamydia granuloma indications;

     6.3.3 [***] dollars ($[***] US) upon filing by Licensee, strategic partner
     or Sublicensee of an NDA with the U.S. Food and Drug Administration for the
     use of antibacterial drugs for treating Chlamydia granuloma

     6.3.4 [***] dollars ($[***] US) upon first commercial sale of Licensed
     Product(s) or Combination Product(s) anywhere in the Licensed Territory;
     and

     6.3.5 [***] dollars ($[***] US) after Licensee's or Sublicensee(s)'s gross
     revenues of Licensed Product(s) or Combination Product(s), reaches [***]
     Dollars [***] ($[***]) in any twelve (12)-month period

6.4 Pre-Commercialization Progress Reports. Until Licensee or any Sublicensees
engage in commercial use or sale of Licensed Product(s) or Combination
Product(s), Licensee shall prepare and submit to University within thirty (30)
days of December 31 of each year a report regarding the progress of Licensee and
any Sublicensee in developing the Licensed Product(s) or Combination Product(s)
for commercial exploitation. Such report shall include such particulars as are
necessary to demonstrate compliance with Licensee's diligence obligations set
forth in this Article 6.0

6.5 Failure to Meet Milestones. If Licensee fails to adhere to the diligence
requirements set forth in this Article 6.0 with respect to Licensed Product(s)
or Combination Product(s), University may terminate the license grants of this
Agreement with respect to such Licensed Product(s) or Combination Product(s) in
accordance with Article 18.0 (Term and Termination).

7.0 LICENSING FEES AND ROYALTIES

7.1 License Issue Fee. As partial consideration for the rights, privileges and
licenses granted hereunder, Licensee shall pay to University a one-time
non-refundable non-creditable license issue fee of [***] dollars ($[***] US) due
and payable according to the following schedule:

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        8

<Page>

     -    [***] dollars (USD $[***] US) within fifteen (15) days of the
          Effective Date, and

     -    [***] dollars (USD $[***] US) within one hundred and eighty (180) days
          of the Effective Date.

7.2 License Maintenance Fee. Licensee shall pay to University [***] dollars
($[***] US) per year, creditable against milestone payments in the corresponding
year, until Licensee makes its first royalty payment. In years with more than
one milestone payment, the license maintenance fee will be waived for the
subsequent year. This license maintenance fee is due and payable at the end of
the quarter that includes the Effective Date of this Agreement.

7.3 Earned Royalty. Licensee shall pay to University an earned royalty of:

     7.3.1 [***] ([***]%) of Net Sales of Licensed Product(s), whether Licensed
     Product(s) is/are sold by Licensee or its Sublicensees; due and payable
     within thirty (30) days of the end of each calendar quarter during the term
     of this Agreement.

     7.3.2 Licensee shall pay earned royalties to University on a quarterly
     basis within thirty (30) days of each of the following dates: March 31,
     June 30, September 30, and December 31 of each year.

7.4 Earned Royalty for Combination Product(s). Where Combination Product(s)
is/are sold, Licensee shall pay an earned royalty based on the following
modification of Net Sales. When the component constituting a Licensed Product(s)
and each component not constituting a Licensed Product(s) have established
market prices in a particular country when sold separately, Net Sales in that
country shall be determined by multiplying the net sales for each such
Combination Product(s) by a fraction, the numerator of which shall be the
established market price for the Licensed Product(s) contained in the
Combination Product(s) and the denominator of which shall be the sum of the
established market price for the Licensed Product(s) plus the established market
price of the other components contained in the Combination Product(s). When such
separate market prices are not established in that particular country, the
Parties shall negotiate in good faith to determine a fair and equitable method
of calculating Net Sales in that country for the Combination Product(s) in
question.

7.5 Minimum Annual Royalties. Regardless of Net Sales, Licensee shall pay
minimum annual royalties to be creditable against earned royalties on a
non-cumulative basis and to be due in full and payable as shown below during the
term of this Agreement according to the following schedule:

     -    Due the first year in which a sale of Licensed Product occurs: [***]
          dollars ($[***] US)

     -    Due the first quarter of the every year thereafter: [***] dollars
          ($[***] US).

Nothing contained in this Paragraph 7.5 shall be construed to in any way alter
or reduce Licensee's obligations under Paragraph 7.3.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        9

<Page>

7.6 No Duplicative Royalties. Except as set forth in this Article 7.0, no
multiple royalties shall be payable to University where any Licensed Product(s)
or Combination Product(s), its manufacture, use, and/or sale is or will be
covered by more than one patent application or issued patent licensed under this
Agreement as part of UW Patent Rights.

7.7 Third Party Royalties. If Licensee is required to pay royalties to a Third
Party based on Licensee's manufacture, use, or sale of Licensed Product(s)
and/or Combination Product(s) subject to one or more patents of such Third
Party, the royalty rate specified in Paragraphs 7.3 and 7.4 shall be reduced by
an equitable amount to be determined through good faith negotiations between
University and Licensee, provided that use of any Third Party patent is required
in connection with such manufacture, use, or sale of Licensed Product(s) and/or
Combination Product(s), and provided that the royalty to University shall not
fall below fifty percent (50%) of that otherwise payable under this Agreement.

7.8 Currency and Exchange Rate. All payments required under this Agreement shall
be made in United States dollars by check, money order or wire transfer to a
bank account as designated by University. All such payments must include the
University invoice number or the contract number [***] on the check or cover
letter. The royalties on sales in currencies other than United States dollars
shall be calculated using the appropriate foreign exchange rate for such
currency as published in The Wall Street Journal (Western edition) on the last
business day of each calendar quarter in which the sales occurred. All non-U.S.
taxes related to royalty payments shall be paid by Licensee and are not
deductible from the payments due University.

7.9 Wire Transfers. If payment is made by wire transfer, such wire transfer must
contain the following information: [***], Office of Technology Licensing, ATTN:
Financial Manager. The wire transfer should be directed towards [***], ABA#
[***], and University budget number ([***]) Bank of America, University Branch,
4701 University Way NE, Seattle, WA 98105-4412, and a copy must be sent via fax
to University OTL Financial Manager and a copy to University OTL Technology
Manager at 206-685-4767. International wires must be paid in United States
dollars and must also include the reference "[***]". In the case of payment made
by wire transfer to fulfill any financial obligation of Licensee under this
Agreement any and all requirements of Article 7 must be met.

7.10 Late Fee. Licensee agrees to pay a late fee for any overdue (i.e., more
than thirty (30) days past due) licensing fee, royalty payment or other payment
due to University under terms of this Agreement. The late fee shall be computed
as the United States prime rate plus two percent (2%), compounded monthly, as
set forth by The Wall Street Journal (Western edition) on the date on which such
payment is due, of the outstanding, unpaid balance. The payment of such a late
fee shall not foreclose or limit University from exercising any other rights it
may have as a consequence of the lateness of any payment.

8.0  SUBLICENSING PAYMENTS AND FEES.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       10

<Page>

8.1 Sublicense Fees. Within sixty (60) days after the end of each Semi-Annual
Period during the term of this Agreement, Licensee shall pay to University an
amount based on any Sublicensing Consideration received by Licensee during such
Semi-Annual Period as follows:

     8.1.1 [***] of any Sublicensing Consideration received from any
     Sublicensee for the grant of a Sublicense of UW Patent Rights and/or UW
     Technology Rights if the Sublicense is executed before publication by
     Licensee or others in a peer reviewed journal of a study that demonstrates
     the effective use of an antibacterial drug for the therapy of arterial
     Chlamydia granuloma; or

     8.1.2 [***] of any Sublicensing Consideration received from any Sublicensee
     for the grant of a Sublicense of UW Patent Rights and/or UW Technology
     Rights if the Sublicense is executed after a first sale of the Licensed
     Product(s) or Combination Product(s) by Licensee.

8.2  Equity.

     8.2.1 Publicly Traded Equity. If Licensee receives consideration in the
     form of publicly traded equity from a Sublicense, all provisions of Article
     8.0 (Sublicensing Payments and Fees) shall apply, except that University
     may, at its sole discretion, elect to receive University's share of such
     equity as either equity or the Fair Market Cash Value (hereinafter defined)
     equivalent of such equity at the time of issuance to Licensee. "Fair Market
     Cash Value" means the average price that the stock in question is publicly
     trading at for twenty (20) days prior to the transfer of the equity to
     Licensee or Affiliate from the Sublicensee.

     8.2.2 Non-publicly Traded Equity. If Licensee receives consideration in the
     form of equity that is not publicly traded from a Sublicense, all
     provisions of Article 8.0 (Sublicensing Payments and Fees) shall apply
     University shall have the right to sell such equity at any time after a
     public or private market for such equity is created.

     8.2.3 If under the provisions of this Paragraph 8.2 University elects to
     receive the equity, such equity shall be in the name "University of
     Washington".

     8.2.4 Notwithstanding the above, it is understood and agreed that
     University shall not be entitled to any portion of amounts received by
     Licensee from Sublicensee(s) for the purchase of equity in Licensee, debt
     financing, research and development, the license or Sublicense(s) of any
     intellectual property other than the UW Patent Rights and/or UW Technology
     Rights, or reimbursement for patent or other expenses.

9.0  PATENT PROSECUTION AND COST RECOVERY.

9.1 University Control of Prosecution. Subject to Paragraph 18.6 University, or
its designees shall have exclusive control over the filing, prosecution and
maintenance of any and all patent applications included in UW Patent Rights,
whether pending or not yet filed as of the Effective

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       11

<Page>

Date of this Agreement, and of the maintenance and other management of any and
all issued patents included in UW Patent Rights during the term of this
Agreement.

9.2 Licensee Role in Prosecution. University shall keep Licensee informed of the
status of any and all new patents and/or patent applications that are part of UW
Patent Rights Licensee may provide comments to University on courses of action
with respect to the filing of new patent applications relating to UW Patent
Rights, prosecution of patent applications within UW Patent Rights, and/or
maintenance of patents within UW Patent Rights, provided University has
exclusive authority to prosecute and maintain UW Patent Rights.

9.3 University Cost Recovery from Licensee. Licensee agrees to reimburse
University for all fees and costs for those actions related to the filing,
prosecution and maintenance of patent applications, including, without
limitation, interference, oppositions, and reexaminations, and maintenance and
defense of patents, in UW Patent Rights, whether incurred prior to the execution
of this Agreement or during the term of this Agreement. Such fees and costs
shall not include costs incurred by the University in the use of its own
resources, such as employee time Licensee agrees to pay invoices for such fees
and costs submitted by University upon receipt of any such invoices. In any case
where Licensee fails to pay fees and costs invoiced to Licensee by University
within sixty (60) days of the date of such invoice, University may file,
prosecute and/or maintain a patent application or patent at its own expense and
for its own exclusive benefit. Licensee shall thereupon forfeit any license
related to the filing, prosecution, and maintenance of patent applications under
such patent or patent application.

     9.3.1 University Cost Recovery from Licensee for Past Costs. Licensee is
     hereby required to pay no later than June 13, 2003 the sum of Twenty
     Thousand Four Hundred Twenty Four Dollars and Fifty One Cents ($20,424.51
     US) to cover the past fees and costs as described above in Paragraph 9.3

     9.3.2 University Cost Recovery from Licensee for Future Costs. Licensee is
     hereby required to pay within thirty (30) days of the Effective Date the
     sum of One Thousand Seven Hundred Sixty Five dollars ($1,765.00) ("Advanced
     Payment") to cover the future fees and costs as described above in
     Paragraph 9.3. The Advanced Payment will be placed in a non-interest
     bearing account to be deposited in a University Advanced Payment account
     University will submit the following documents to Licensee on a quarterly
     basis: 1) an invoice which will summarize all costs and fees that have been
     paid by University in support of the UW Patent Rights for the immediately
     preceding quarter; 2) copies of all legal invoices paid by the University
     during the immediately preceding quarter; and 3) either a report
     identifying any unused portion of the Advanced Payment to be applied to the
     next quarter's fees and costs or, if the Advanced Payment has been
     depleted, a request for additional funds to replenish the Advanced Payment
     account. The determination of the amount of additional funds necessary for
     the Advanced Payment account will be made solely by the University and will
     be based on the patent attorney's estimate for the upcoming year's fees and
     costs. Upon termination of this Agreement, any unexpended balance of the
     Advanced Payment will be held by University to pay outstanding fees and
     costs as described in Paragraph 9.3, and the unused portion refunded to
     Licensee within ninety (90) days after University's final accounting
     University may, at University's sole discretion, apply any such unused

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       12

<Page>

     portion of the Advanced Payment toward the payment of other monies Licensee
     owes University under this Agreement. The Parties agree that in
     establishing the Advance Payment account no fiduciary relationship between
     them is created, and that University's duties with regard to the Advance
     Payment are limited to those explicitly stated herein.

10.0 REPORTS

10.1 Quarterly Report. With each payment to University, Licensee shall include a
report setting forth the relevant details of the business conducted by Licensee
and each Sublicensee, if applicable, during the preceding calendar quarter
pursuant to their obligations under Paragraph 7.3 of this Agreement. This
report, for Licensee and each Sublicensee, shall include, at a minimum, the
following:

     10.1.1 the number of units of Licensed Product(s) and Combination
     Product(s) manufactured, used, or sold and by country within the Licensed
     Territory;

     10.1.2 the gross amounts invoiced for Licensed Product(s) and Combination
     Product(s);

     10.1.3 any and all discounts or allowances, and description of same,
     granted to Third Parties; and

     10.1.4 the calculation of total amounts due University

11.0 RECORD KEEPING

11.1 Records Retained. Licensee shall keep complete and accurate records and
books of account containing all information necessary for the computation and
verification of the amounts to be paid hereunder. Licensee shall keep these
records and books for a period of five (5) years, or longer if required by law,
following the end of the accounting period to which the information pertains.

11.2 Auditing Rights. Licensee agrees, at the request of University, to permit
one or more accountants selected exclusively by the University ("Accountants")
to have access to Licensee's records and books of account pertaining to this
Agreement during ordinary working hours to audit with respect to any payment
period ending prior to such request, the correctness of any report or payment
made under this Agreement, or to obtain information as to the payments due for
any such period in the case of failure of Licensee to report or make payment
pursuant to the terms of this Agreement.

11.3 Scope of Disclosure. The Accountant shall not disclose to University any
information relating to the business of Licensee except that which is necessary
to inform University of:

     11.3.1 the accuracy or inaccuracy of Licensee's reports and payments;

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       13

<Page>

     11.3.2 compliance or noncompliance by Licensee with the terms and
     conditions of this Agreement; and

     11.3.3 the extent of any inaccuracy or noncompliance.

11.4 Accountant Copies. Should the Accountant believe there is an inaccuracy in
any of Licensee's payments or noncompliance by Licensee with any of such terms
and conditions, the Accountant shall have the right to make and retain copies
(including photocopies) of any pertinent portions of the records and books of
account.

11.5 Costs of Audit. In the event that Licensee's royalties calculated for any
quarterly period are under reported by more than three percent (3%), the costs
of any audit and review initiated by University will be borne by Licensee;
otherwise, University shall bear the costs of any audit initiated by University.

12.0 PATENT INFRINGEMENT

12.1 Mutual Notice. Each Party shall promptly inform the other Party of any
alleged infringement of UW Patent Rights by a Third Party of which it becomes
aware, and provide to the other Party with any available evidence thereof

12.2 Licensee First Right to Settle During Term of Exclusivity. During the term
of exclusivity of the license granted hereunder, Licensee shall have the first
right to respond to, defend, and prosecute in its own name actions or suits
relating to UW Patent Rights. Licensee shall not settle any suits or actions in
any manner relating to the UW Patent Rights, however, where the settlement
adversely and materially affects the validity, enforceability, or existence of
UW Patent Rights without obtaining the prior written consent of University,
which consent shall not be unreasonably withheld or delayed. To enjoy said first
right, Licensee must initiate bona fide action to respond to any alleged
infringement within ninety (90) days of learning of said infringement. In the
event that University consents to settlement by Licensee, the proceeds from such
settlement will be distributed as follows: after Licensee has recovered its
reasonable attorneys' fees and other out-of-pocket expenses directly related to
any action, suit, or settlement for infringement of UW Patent Rights in the
Field of Use, University and Licensee shall divide any remaining damages,
awards, or settlement proceeds in the following manner:

University:   Twenty Percent (20%)
Licensee:     Eighty Percent (80%)

Any payment by an alleged infringer that constitutes consideration for Net
Sales, however, shall be handled according to the payment provisions of Article
7.0 (Licensing Fees and Royalties). Any payment by an alleged infringer that
constitutes consideration for the grant of a Sublicense, however, shall be
handled according to the applicable payment provisions for Sublicenses set forth
in this Agreement.

12.3 Voluntary Participation by University. In the event Licensee institutes
suit against an alleged infringer during the term of exclusivity as provided in
this Agreement, then University

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       14

<Page>

may agree to voluntarily participate as a named party at its sole discretion. If
University decides not to voluntarily participate in such suit, then University
agrees to be bound by any final judgment rendered by the court. Further, if
University chooses not to voluntarily participate but the court determines
University is a necessary or indispensable party, then Licensee agrees to pay
all University's reasonable attorneys' fees and other out-of-pocket direct
associated expenses, and University agrees to make reasonable efforts to
cooperate and assist Licensee in connection with the suit.

12.4 University Right to Institute Action. If Licensee fails, within ninety (90)
days of learning of an alleged infringement, to secure cessation of the
infringement, institute suit against the infringer, or provide to University
satisfactory evidence that Licensee is engaged in bona fide negotiation for the
acceptance by infringer of a Sublicense in and to relevant patents in UW Patent
Rights for the Field of Use, University may then, upon written notice to
Licensee, assume full right and responsibility to secure cessation of the
infringement, institute suit against the infringer, or secure acceptance of a
Sublicense from Licensee in and to relevant patents in UW Patent Rights,
approval for which Sublicense Licensee shall not unreasonably withhold. If
University in accordance with the terms and conditions of this Agreement chooses
to institute suit against an alleged infringer, University may bring such suit
in its own name (or, if required by law, in its and Licensee's name) and at its
own expense, and Licensee shall, but at University's expense for Licensee's
direct associated expenses, fully and promptly cooperate and assist University
in connection with any such suit. Any and all damages, awards, or settlement
proceeds arising from such a University initiated action shall be University's.

12.5 No Obligation to Institute Action. Neither Licensee nor University is
obligated under this Agreement to institute a suit against an alleged infringer
of UW Patent Rights.

13.0 PATENT VALIDITY

13.1 Licensee Notice to University of Third Party Actions. If any claim
challenging the validity or enforceability of any of the UW Patent Rights shall
be brought against Licensee, Licensee shall promptly notify University.
University, at its sole discretion, shall have the right, within thirty (30)
days after notification by Licensee of such action, to intervene and take over
the sole defense of the claim at University's expense. If University opts not to
intervene and take over the sole defense of the claim within thirty (30) days
after notification by Licensee, Licensee shall have the right to control the
defense of the claim at its own expense.

13.2 Covenant Not to Challenge UW Patent Rights. Licensee agrees during the term
of this Agreement not to challenge the validity or enforceability of any of the
UW Patent Rights.

14.0 PATENT MARKING. Licensee shall mark any and all material forms of Licensed
Product(s), Combination Product(s) or packaging pertaining thereto made and sold
by Licensee in the United States with an appropriate patent marking identifying
the pendency of any US patent application and/or any issued U.S. or foreign
patent forming any part of the UW Patent Rights. All product(s) shipped or sold
in other countries shall be marked in such a manner as to provide

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       15

<Page>

notice to potential infringers pursuant to the patent law and practice of the
country of manufacture or sale.

15.0 USE OF NAMES. Nothing contained in this Agreement shall be construed as
conferring any right to use in advertising, publicity or other promotional
activities any name, trade name, trademark, or other designation of University
without the express written permission of University, unless such listing is
required under local laws or regulations, provided that Licensee may state the
existence of this Agreement and the fact that both Parties entered into it For
any use other than the foregoing, Licensee hereby expressly agrees not to use
the name "University of Washington" or any contraction, abbreviation, or
simulation thereof without prior written approval from an authorized
representative of University If University or Licensee wishes to issue a press
release or make any other public announcement relating to the Agreement, the
Parties will consult with one another in advance on the content to ensure the
medical and scientific accuracy of the announcement and to ensure that such
press release or other public announcement does not contain Confidential
Information. In any event, no press release or other public announcement shall
be issued without the express written authorization of the Parties, and the
Parties agree to expedite the approval of each other's press releases

16.0 REPRESENTATIONS AND WARRANTIES

16.1 Right to Grant License. University represents and warrants that it has the
right to grant the license in and to the UW Patent Rights and disclose the UW
Technology Rights set forth in this Agreement.

16.2 DISCLAIMER OF WARRANTY. UNIVERSITY EXPRESSLY DISCLAIMS ANY AND ALL
WARRANTIES, WHETHER EXPRESS OR IMPLIED, PERTAINING TO THE MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE OF THE UW PATENT RIGHTS, UW TECHNOLOGY RIGHTS,
LICENSED PRODUCT(S), OR ANYTHING ELSE LICENSED, DISCLOSED, OR OTHERWISE PROVIDED
TO LICENSEE UNDER THIS AGREEMENT

Nothing in this Agreement shall be construed as:

     16.2.1 A representation or warranty by University as to the patentability,
     validity, scope, or usefulness of the UW Patent Rights; or

     16.2.2 A representation or warranty by University that anything made, used,
     sold, or otherwise disposed of under any license granted in this Agreement
     is or will be free from infringement of patents or other proprietary rights
     not included in the UW Patent Rights

16.3 LIMITATION OF LIABILITY OF UNIVERSITY. UNIVERSITY'S MAXIMUM LIABILITY UNDER
THIS AGREEMENT IS LIMITED TO THE COSTS AND FEES PAID TO UNIVERSITY UNDER THIS
AGREEMENT. UNIVERSITY WILL NOT BE LIABLE DIRECTLY OR INDIRECTLY FOR ANY PROPERTY
DAMAGE, PERSONAL INJURY

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       16

<Page>

LOSS OF USE, INTERRUPTION OF BUSINESS, LOSS OF PROFITS, OR OTHER SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED, WHETHER FOR BREACH OF
WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE

16.4 Representations by Licensee, Licensee represents that it has the right and
authority to enter into this Agreement and that it has listed all Affiliates as
of the Effective Date in Exhibit 1.2

17.0 INDEMNIFICATION AND INSURANCE

17.1 Licensee Indemnification of University. Licensee agrees to indemnify, hold
harmless, and defend University, its regents, officers, inventors, employees,
students, and agents ("Indemnified Parties") against any and all claims, causes
of action, lawsuits, or other proceedings ("Claims") and losses, damages, costs,
fees, and expenses ("Costs") filed, instituted, resulting from, or arising out
of the design, process, manufacture, use, possession, or operation by any person
or party (including Sublicensees) of UW Patent Rights, UW Technology Rights, any
products based on or incorporating UW Patent Rights or UW Technology Rights, or
any other embodiment of UW Patent Rights or UW Technology Rights Licensee agrees
to such indemnification even though such Claims or Costs related thereto are
based upon doctrines of strict liability or product liability Such indemnity
shall not, however, apply to Claims arising from the gross negligence or
intentional misconduct of any Indemnified Party This indemnification clause
shall survive the termination of this Agreement

17.2 Licensee Liability Insurance. Licensee shall maintain general liability
insurance including, but not limited to, product liability and contractual
liability coverage at an amount customary to Licensee's business for activities
and/or products of a similar nature that shall be in effect no later than the
date of the first human clinical testing of Licensed Product(s) and/or Combined
Product(s), Licensee's general liability insurance shall name University as an
additional insured Licensee shall declare whether the insurance is provided on a
"claims-made" form and must notify University within three (3) business days if
coverage is canceled

17.3 Human Clinical Trials. Licensee shall provide to University within thirty
(30) days prior to the initiation of human clinical trials with respect to
Licensed Product(s), certificates evidencing the existence and amount of the
insurance required under Article 18.0 (Term and Termination). Licensee shall
issue irrevocable instructions to its insurance agent and to the issuing
insurance company to notify University of any discontinuance or lapse of such
insurance not less than thirty (30) days prior to the time that any such
discontinuance is due to become effective Licensee shall provide University a
copy of such instructions upon their transmittal to the insurance agent and
issuing insurance company Licensee shall further provide University, at least
semi-annually, proof of continued coverage

18.0 TERM AND TERMINATION

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       17

<Page>

18.1 Term. The term of this Agreement shall commence on the Effective Date and
shall continue until the last of UW Patent Rights expires, unless sooner
terminated in accordance with the provisions set forth under this Article 18.0.

18.2 Material Breach By Licensee. University may terminate this Agreement
effective upon thirty (30) days prior written notice of termination to Licensee,
if Licensee materially breaches this Agreement and does not cure such breach
within sixty (60) days after receiving such notice. Licensee agrees that any and
all commercialization diligence requirements and required payments are material
license terms according to Articles 6.0 (Diligence and Development Milestones),
7.0 (Licensing Fees and Royalties), 8.0 (Sublicensing Payments and Fees) and 9.0
(Patent Prosecution and Cost Recovery). In the event that Licensee has breached
any such obligation with respect to Licensed Product(s) or Combination
Product(s), the University may, in its sole discretion, terminate the license
granted herein with respect to the UW Patent Rights and/or UW Technology Rights
relating to such Licensed Product(s) or Combination Product(s), while retaining
the remainder of this Agreement in full force and effect.

18.3 At-Will Termination By Licensee. Licensee may terminate this Agreement
effective upon sixty (60) days prior written notice if in Licensee's reasonable
opinion it will not commercialize the UW Patent Rights.

18.4 Insolvency. This Agreement, and the license granted to Licensee hereunder,
shall terminate immediately in the event that:

     18.4.1 Licensee seeks liquidation, reorganization, dissolution or is
     insolvent or evidence exists as to its insolvency or winding up of itself,
     or makes any general assignment for the benefit of its creditors;

     18.4.2 a petition is filed by or against Licensee, or any proceeding
     against Licensee as a debtor, under any bankruptcy or insolvency law,
     unless the laws then in effect void the effectiveness of this provision;

     18.4.3 a receiver, trustee, or any similar officer, under bankruptcy law,
     is appointed to take possession, custody or control of all or part of
     Licensee's assets or property; or

     18.4.4 Licensee adopts any resolution of its Board of Directors or
     stockholders for the purpose of effecting any of the foregoing

18.5 No Further Rights. Upon termination, Licensee shall have no further rights
under either the UW Patent Rights or the UW Technology Rights

18.6 Financial Obligations. Termination by University or Licensee under the
options set forth in this Agreement shall not relieve Licensee from any
financial obligation to University accruing prior to termination or from
performing according to any and all other provisions of this Agreement that
survive termination

18.7 Other Remedies. The provisions under which this Agreement may be terminated
shall be in addition to any and all other legal remedies which either Party may
have for the enforcement

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       18

<Page>

of any and all terms hereof, and do not in any way limit any other legal remedy
such Party may have

19.0 ASSIGNMENT

19.1 University Consent Required. This Agreement may not be assigned by Licensee
without the express written consent of University except that Licensee may
assign or otherwise transfer this Agreement and the license granted hereby and
the rights acquired by it hereunder so long as such assignment or transfer shall
be accompanied by a sale or other transfer of Licensee's entire business or of
the entirety of that part of Licensee's business to which the license granted
hereby relates, including a change of control Licensee shall give University
thirty (30) days prior notice of such assignment and transfer. Upon such
assignment or transfer, the term "Licensee" as used in this Agreement shall
include such assignee or transferee and this Agreement shall be binding upon
Licensee's permitted successors and assigns

19.2 University Assignment. University may assign or otherwise transfer this
Agreement and the license granted hereby and the rights acquired by it
hereunder. University shall give Licensee thirty (30) days prior notice of such
assignment and transfer. Upon such assignment or transfer by such assignee or
transferee, the term University herein shall include such assignee or transferee
and this Agreement shall be binding upon University's permitted successors and
assigns.

20.0 NOTICE OR DEMAND

20.1 Written Notice Required. All notices, requests, and other communications
required or permitted under this Agreement shall be in writing, shall refer
specifically to this Agreement and the OTL # 1168-1291129DL, and shall be deemed
delivered upon receipt. If delivered by United States mail, postage should be
prepaid by certified return receipt. If sent by facsimile (provided that a
transmittal sheet indicates confirmation), or other electronic transmission, a
confirmation copy will be forwarded. Any such notices, requests, and other
communications shall be addressed as follows:

LICENSEE:     ActivBiotics, Inc.
              128 Spring Street
              Lexington, MA
              Attn : Chalom Sayada, MD Ph.D.
              Chief Executive Officer, ActivBiotics Inc
              Main: 781-372-4800
              Direct: 781-372-4806
              Fax: 781-274-8638

UNIVERSITY:   University of Washington
              Office of Technology Licensing
              Attn: Director
              4311 11th Avenue NE, Suite 500

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       19

<Page>

              Seattle, WA 98105
              Fax: 206-685-4767

20.2 Change of Address. Either Party, by notice, may change the address to which
notice will be sent and unless so notified of a change of address all notices
mailed to Licensee or University at the above stated address will be deemed
sufficient

21.0 EXPORT CONTROLS. Licensee acknowledges and agrees that University is
subject to United States laws and regulations controlling the export of
technical data, computer software, laboratory prototypes, and other commodities
(including without limitation the Arms Export Control Act, the Export
Administration Act of 1979 and the U.S., Patriot Act, and including all
amendments thereof), and that its obligations hereunder are contingent on
compliance with applicable United States export laws and regulations. The
transfer of certain technical data and commodities may require a valid export
license from the cognizant agency of the United States Government and/or written
assurances by Licensee that Licensee shall not export data or commodities to
certain foreign countries without prior approval of such agency University does
not represent that an export license shall be required, nor does it represent
that such an export license shall be issued Licensee hereby agrees that Licensee
shall not export or re-export, directly or indirectly, any Licensed Product(s)
and/or UW Patent Rights and/or UW Technology Rights to any country for which the
United States Government or other competent authority at the time of export
requires an export license or other approval, without first obtaining such
license or approval from the appropriate governmental authority; obtaining such
permission will be the sole responsibility of Licensee

22.0 DISPUTE RESOLUTION. The Parties shall attempt to resolve through good faith
discussions any dispute, which arises under this Agreement. Any dispute may, at
the election of either Party, be referred to the Licensee's Chief Executive
Officer and University's Director of Technology Licensing, or their authorized
representatives

23.0 ATTORNEYS' FEES. The substantially prevailing party in arbitration or in
any judicial or administrative action or proceeding arising under or in
connection with this Agreement shall be entitled to reimbursement from the other
party for its reasonable costs and attorneys' fees, including those on appeal,
and including without limitation, the cost at the hourly charges routinely
charged by the person providing the services, the time of legal assistants,
secretarial and clerical overtime, and fees and expenses of experts retained by
counsel

24.0 PROPRIETARY RIGHTS. Licensee will not, by performance under this Agreement,
obtain any ownership interest in the UW Patent Rights and/or UW Technology
Rights or any other proprietary rights or information of University, its
officers, inventors, employees, students, or agents.

25.0 SEVERABILITY. If any provision of this Agreement is determined to be
unenforceable or otherwise unlawful, then such provision will be without effect,
and the remaining terms and conditions of this Agreement will survive, as if
such provision had not been included herein. The

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       20

<Page>

Parties will promptly meet to agree upon further terms which will, within the
confines of the law, most substantially satisfy the intention of the Parties as
reflected by the ineffective provision

26.0 HEADINGS AND CAPTIONS. The headings and captions of the Articles of this
Agreement are for convenience of reference only and in no way define, limit or
affect the scope or substance of any Article of this Agreement

27.0 SURVIVAL. Article 17.0 (Indemnification and Insurance), Article 23.0
(Attorneys' Fees), and Paragraph 28.1 (Choice of Law/Venue), and other
provisions that by their context would survive, shall survive the termination of
this Agreement.

28.0 MISCELLANEOUS

28.1 Choice of Law/Venue. Because University is a public institution with its
central administrative offices in Seattle, Washington, and because of the
critical role played by University in administrating terms of this Agreement,
the Parties agree this Agreement shall be governed by and interpreted in
accordance with the laws of the state of Washington, regardless of its conflict
of law provisions. The Parties further agree that any claim related in any
manner to the Agreement shall be instituted and commenced in, and venue shall be
either King County, Washington or the United Stated District Court for the
Western District of Washington

28.2 Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of both Parties and their respective successors and assigns,
including any corporation or entity with which or into which either Party may be
merged or which may succeed to its assets or business

28.3 Non-Agency. With respect to the subject matter of this Agreement, Licensee
and University are independent contractors and neither shall be deemed to be an
agent, employee, partner, nor joint-venturer of the other for any purpose

28.4 Waiver. No delay or omission by either Party in exercising any right under
this Agreement shall operate as a waiver of that or any other right. A waiver or
consent given by either Party on any one occasion is effective only in that
instance and shall not be construed as a bar to or waiver of any right on any
other occasion

28.5 Entire Agreement. The Parties hereto acknowledge that this Agreement,
together with the Exclusive Option Agreement Between ActivBiotics, Inc. and the
University of Washington, dated June 13, 2002, sets forth the entire Agreement
and understanding of the Parties hereto as to the subject matter hereof,
supersedes any and all prior written and oral agreements, understandings or
offers. This Agreement shall be operative in the event of inconsistencies with
any other agreement. This Agreement may not be modified, changed or discharged
in whole or in part, except by an agreement in writing signed by authorized
representatives of both Licensee and University

IN WITNESS WHEREOF, THE PARTIES HAVE EACH READ AND BY SIGNATURE OF THIS
AGREEMENT AGREE TO BE LEGALLY BOUND BY ALL OF THE ATTACHED

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       21

<Page>

TERMS AND CONDITIONS, ALL OF WHICH ARE INCORPORATED FULLY INTO THIS AGREEMENT,
AND HAVE CAUSED THIS AGREEMENT TO BE EXECUTED BY THEIR DULY AUTHORIZED
REPRESENTATIVES.

ACTIVBIOTICS INC.                       UNIVERSITY OF WASHINGTON

By: /s/ Chalom B. Sayada                By: /s/ James A. Severson
    ---------------------------------       ------------------------------------

Name: Chalom B. Sayada, M.D., Ph.D.     Name: James A. Severson

Title: CEO                              Title: Vice Provost, Intellectual
                                               Property and Technology Transfer

Date: June 2, 2003                      Date: May 19, 2003

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       22

<Page>

                                    EXHIBIT A

          Exclusive Option Agreement Between ActivBiotics, Inc. and the
                            University of Washington

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       23

<Page>

                           EXCLUSIVE OPTION AGREEMENT

                                     BETWEEN

               ACTIVBIOTICS, INC. AND THE UNIVERSITY OF WASHINGTON

THIS EXCLUSIVE OPTION AGREEMENT ("Agreement") is entered into on June 13th, 2002
("Effective Date") by and between ActivBiotics, Inc., a Delaware corporation
with its principal place of business at Broadway Street 198, Cambridge, MA
02139 ("Company") and the University of Washington, a public institution of
higher education and an agency of the state of Washington acting through its
Office of Technology Licensing, with administrative offices at 1107 NE 45th
Street, Suite 200, Seattle, WA 98105 ("University").

1. Recitals.

1.1 Whereas, University has developed and owns or is in possession of certain
technology ("UW Technology" defined below) relating to Diagnosis and Treatment
of Arterial Chlamydial Granuloma;

1.2 Whereas, Company is an early stage pharmaceutical company focusing on the
development of cures for chronic and infectious diseases;

1.3 Whereas, Company is willing to support the preparation, filing, prosecution
and maintenance of certain patent applications or issued patents covering all or
part of UW Technology and is willing to devote corporate resources directed
towards the support and development of UW Technology;

1.4 Whereas, University is willing to grant Company an option to obtain an
exclusive, worldwide, royalty bearing license to UW Patent Rights in the Field
of Use under the terms and conditions of this Agreement;

Now, therefore, in consideration of the mutual promises set forth herein, and
other good and valuable consideration, the receipt and sufficiency of which is
hereby expressly acknowledged, the University and Company (collectively "the
Parties") hereby agree as follows:

2. Definitions.

2.1 "UW Technology" shall mean technology related to Diagnosis and Treatment of
Arterial Chlamydial Granuloma as developed in the University laboratory by Dr(s)
Cho Cho Kuo, Allan Shor, Dorothy L. Patton, Lee Ann Campbell and I Thomas
Grayston and as recorded in OTL file # 1169-1291129DL

2.2 "UW Inventors" shall mean Drs Cho Chuo Kuo and Dr Allan Shor.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

2.3 "UW Patent Rights" shall mean the United States Patents listed below and any
corresponding US patent issued therefrom, including all reissues, divisionals,
continuations, reexaminations and extensions thereof, together with all
corresponding foreign patents, extensions, supplemental protection certificates
and applications corresponding thereto now issued or issued during the term of
the license agreement and which directly relate to UW Technology. A patent or
patent application shall cease to be a UW Patent Right when any of the following
occur: a) it expires; b) it is abandoned; or c) it is held to be unenforceable
by a court of competent jurisdiction from which no appeal can be taken. Issued
patents as of the Effective Date are:

United States Patent Number:     US6,043,225
Title:                           Diagnosis and Treatment of Arterial Chlamydial
                                 Granuloma
Application Date:                3/28/2000
Assignee:                        University of Washington and Allan Shor*

United States Patent Number:     US5,830,874
Title:                           Diagnosis and Treatment of Arterial Chlamydial
                                 Granuloma
Application Date:                11/3/1998
Assignee:                        University of Washington and Allan Shor*

United States Patent Number:     US5,424,187
Title:                           Diagnosis and Treatment of Arterial Chlamydial
                                 Granuloma
Application Date:                6/13/1995
Assignee:                        University of Washington and Allan Shor*

*    Exclusively controlled by University of Washington under separate agreement
     with Shor evidence of which is given in Appendix B.

2.4 "Technical Information" shall mean any technical facts, data, or advice,
written or oral (in the form of information contained in patents and patent
applications, reports, letters, drawings, specifications, testing procedures,
training and operational manuals, bills of materials, photographs and other
materials) directly related to UW Technology and which is owned or in the
possession of University, delivered to Company by University and not subject to
third party rights.

2.5 "Field of Use" shall mean Diagnosis and Treatment of Arterial Chlamydial
Granuloma, which includes related arterial and coronary diseases or disorders
caused or influenced by chlamydial infections.

3. Grant of Option, Exercise of Option, and Option Period.

3.1 Grant. Provided that Company complies with obligations set forth under this
Agreement, University hereby grants to Company a time-limited option to
negotiate a royalty-bearing,

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

limited-term, worldwide exclusive license on commercially reasonable terms under
the UW Patent Rights in the Field of Use to make, have made, use, sell, and
offer to sell products that use or are derived from the UW Patent Rights in the
Field of Use.

     3.1.1 The option granted above, and any license granted pursuant thereto,
is subject to a reserved right by the University, with the right to
non-exclusively sublicense to non-profit institutions, to make, have made, and
use products, processes, or other subject matter covered by the UW Patent
Rights, UW Technology or Technical Information for internal research,
instructional and/or other academic purposes. University shall have the right to
use the UW Patent Rights, UW Technology or Technical Information for its own
internal, research, including sponsored research and academic collaborations
during the term of this Agreement. University shall also have the right to
publish any information included in the UW Patent Rights, UW Technology or
Technical Information or any information that may result from their research in
this area.

     3.1.2 Article 3.1 notwithstanding, Company acknowledges that UW Patent
Rights involve federal research funding. Company acknowledges that University
has obligations ("Obligations") under federal law, and actions taken by
University to fulfill such obligations shall not be deemed inconsistent with
University's obligations under this Agreement nor any license agreement granted
pursuant thereto. Company acknowledges that Obligations include, without
limitation, the granting of a worldwide non-exclusive, royalty-free license for
any such UW Patent Rights, by University to the United States Government, and a
statement of United States Government patent rights on all the patents and
patent applications within the UW Patent Rights. Company acknowledges that any
and all determinations of federal funding involvement shall be made solely by
University and University's determination shall be honored by Company.

3.2 Option Period/Option Period Extension. The option shall expire on the
earlier of either (a) execution of a license or (b) 1 year from the Effective
Date of the Agreement. If at the one (1) year anniversary of the Effective
Date of the Agreement the option has not been exercised, the Company shall
have the right to extend the option period ("Option Period Extension") for a
fee of [***] dollars ([***]USD) for an additional year. The Option Period
Extension shall expire the earlier of either (a) execution of a license or
(b) one (1) years from the Effective Date of the extension.

3.3 Commercialization Prohibited During the term of this Agreement. Company
shall have the right to use the UW Patent Rights and Technical Information for
research only. Company is expressly prohibited from selling any products or
services or developing any salable product or service based on the UW Patent
Rights or Technical Information until such time as a license agreement has been
fully executed between the parties.

3.4 Mutual Confidentiality. During the Option Period, Company shall maintain the
UW Technology, UW Patent Rights and Technical Information in confidence and
refrain from disclosing information related to UW Technology, UW Patent Rights
or Technical Information to a third party. In no event shall Company disclose,
or otherwise use UW Technology, UW Patent Rights or Technical Information in
connection with any patent application filed or on behalf of the Company.
Company agrees to restrict the use of UW Technology, UW Patent Rights and
Technical Information exclusively to the terms of this Agreement, provided that
such restriction does not include information that is in the public domain or
which company can show as derived prior to or independently from information
received from University. University's OTL (Office

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

Technology of Licensing) shall maintain in confidence and refrain from
disclosing proprietary Company information, including strategic business plans,
information regarding research, research plans, experimental results or other
proprietary information regarding the business of the Company to the extent
permitted by law. The University of Washington is a governmental agency of the
state of Washington and is subject to the Washington Public records Act, RCW
42.17.250 et seq., and no obligation assumed by University under this Agreement
shall be deemed to be inconsistent with University's obligations defined under
RCW 42.17. University shall provide notice to Company in a timely manner such
that Company is afforded sufficient time to review such documents and/or seek a
protective order, at Company's expense. The responsibility for protecting the
Confidential Information shall reside exclusively with Company utilizing the
procedures described in RCW 42.17.330

3.5 Exercise of Option. If Company wants to exercise the option hereunder it
must provide written notice to University within the term of this Agreement and
provide the University with an acceptable development plan that is similar in
scope and substance to that outlined in Exhibit A attached hereto. The Parties
agree to negotiate the terms of a license in good faith.

4. Option Fee and Payments.

4.1 Fee. As consideration for the option granted by University to Company for
the Option Period, Company agrees to pay to University a non-refundable,
non-creditable option fee of [***] Dollars (US$[***]), due within thirty (30)
days of the Effective Date of this Agreement.

4.2 Patent Prosecution and Cost Recovery

     4.2.1 During the Option Period, University, or its designee, shall have
sole control over the filing, prosecution and maintenance of any and all patent
applications included in UW Patent Rights, whether pending or not yet filed as
of the Effective Date of this Agreement, and of the maintenance and other
management of any and all issued patents included in UW Patent Rights

     4.2.2 During the Option Period, University shall keep Company informed of
the status of any and all new patents and/or patent applications that are part
of UW Patent Rights Company may provide comments to University on courses of
action with respect to the filing of new patent applications relating to UW
Technology, prosecution of patent applications, and/or management of patents in
UW Patent Rights, provided University shall have exclusive authority to
prosecute and maintain UW Patent Rights

     4.2.3 Company agrees to reimburse University for all fees and costs related
to the filing, prosecution and maintenance of patent applications, including,
without limitation, interference, oppositions, and reexaminations, and
maintenance and defense of patents, in patent fees and costs relating to UW
Patent Rights, whether incurred prior to the execution of this Agreement or
during the term of this Agreement. Such fees and costs shall not include costs
incurred by the University in the use of its own resources, such as employee
time, and shall not extend to patenting fees and costs incurred by University
after termination of this Agreement. Company agrees to pay invoices for
previously incurred fees and costs submitted by University in the amount of
Forty Thousand Eight Hundred and Forty-nine Dollars and Two cents
($40,849.02USD) according to the following schedule:

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

                    -    Six (6) Months after the Effective date of this
                         Agreement: Twenty Thousand Four Hundred and Twenty-five
                         Dollars and Fifty-two Cents ($20,425 52USD);

                    -    Twelve (12) Months after the Effective Date of this
                         Agreement: Twenty Thousand Four Hundred and Twenty-five
                         Dollars and Fifty-two Cents ($20,425 52USD)

5. Termination

5.1 Termination by Company. Company has the right to terminate this Agreement
provided that Company gives University sixty (60) days prior written notice of
termination. Termination will be effective sixty (60) days from the date
University receives such notice.

5.2 Termination by University. University shall have the right to terminate this
Agreement, including the option granted to Company in Article 3.1, effective
immediately upon written notice of termination to Company in the event that
Company fails to meet the obligations of Articles 3.3, 3.4, 4.1, or 4.2.3 under
this Agreement and such failure or breach continues unremedied for a period of
sixty (60) days after receipt by Company of written notice thereof from
University. Termination will be effective sixty (60) days after the date Company
receives such notice and only in the event that Company does not cure the
failure or breach within that sixty (60) day period;

5.3 Automatic Termination. This Agreement, and the option granted to Company
hereinabove, shall terminate immediately in the event that (a) Company seeks
liquidation, reorganization, dissolution or winding-up of itself, is insolvent
or evidence exists as to its insolvency, or Company makes any general assignment
for the benefit of its creditors; (b) a petition is filed by or against Company,
or any proceeding is initiated by or against Company, or any proceeding is
initiated against Company as debtor, under any bankruptcy or insolvency law; or
(c) receiver, trustee, or any similar officer is appointed to take possession,
custody, or control of all or any part of Company's assets or property.

6. License Terms.

Upon University's receipt of notice and a development plan reasonably acceptable
to University pursuant to Article 3.5, University and Company shall enter into
good faith negotiations regarding the terms of a license agreement.

7. Miscellaneous Provisions.

7.1 Limitation of Liability of University. No term or provision of this
Agreement shall be construed as a warranty or representation by University
concerning the validity, scope or value of UW Technology, UW Patent Rights or
Technical Information. With respect to the subject matter of this Agreement,
Company and University are independent contractors and neither shall be deemed
to be an agent, employee, partner, nor joint-venturer of the other for any
purpose.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

7.2 Indemnification. Company agrees to indemnify, hold harmless and defend
University, its regents, officers, inventors, employees, students, and agents
("Indemnified Parties") against any and all claims, causes of action, lawsuits,
or other proceedings ("Claims") and losses, damages, costs, fees and expenses
("Costs") filed, instituted, resulting from or arising out of the design,
process, manufacture or use by any person or party, of any Company Products
based on UW Patent Rights, UW Technology or Technical Information. Company
agrees to such indemnification even though such Claims or Costs related thereto
result in whole or in part from the negligence of any of the Indemnified Parties
or are based upon doctrines of strict liability or products liability. Such
indemnity shall not, however, apply to Claims arising from the gross negligence
or intentional misconduct of any Indemnified Party. This indemnification clause
shall survive the termination of this Agreement.

7.3 Entire Agreement. The Parties hereto acknowledge that this Agreement sets
forth the entire Agreement and understanding of the Parties hereto as to the
subject matter hereof and supersedes any and all prior written and oral
agreements, understandings or offers. This Agreement may not be modified,
changed or discharged in whole or in part, except by an agreement in writing
signed by authorized representatives of both Company and University.

7.4 Choice of Law/Venue. Because University is an agency of the state of
Washington, the Parties agree that this Agreement shall be governed by and
interpreted in accordance with the laws of the state of Washington, regardless
of choice of law provisions. The parties further agree that any claim related in
any manner to the Agreement shall be instituted and commenced in, and venue
shall be King County, Washington or the United States District Court for the
Western District of Washington.

7.5 Severability. Should any provision of this Agreement be determined to be
unenforceable or otherwise unlawful, then such provision shall be without
effect, and the remaining terms of this Agreement will survive, as if such
provision had not been included herein; and the Parties shall promptly meet to
agree upon further terms which shall, within the confines of the law, most
substantially satisfy the intention of the Parties as reflected by the
ineffective provision.

7.6 Waiver. No delay or omission by either Party in exercising any right under
this Agreement shall operate as a waiver of that or any other right. A waiver or
consent given by either Party on any one occasion is effective only in that
instance and shall not be construed as a bar to or waiver of any right on any
other occasion.

7.7 Notices and Reports. All notices, requests and other communications to
Company or University hereunder shall be in writing (including fax only if
transmittal sheet indicates confirmation), shall refer specifically to this
Agreement and shall be personally delivered or sent by fax or other electronic
transmission or by registered mail, or certified mail, return receipt requested,
postage prepaid, in each case to the respective addresses listed below (or to
such address as may be specified in writing to the other party hereto):

If to Company:

Active Biotics, Inc.
198 Broadway Street
Cambridge, MA 02139
Attn: Chief Executive Officer

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

Fax: 1-617-497-9688

If to University:

University of Washington
Office of Technology Licensing
1107 NE 45th St. Suite 200
Seattle, WA 98105
Attn: Director
Fax: (206)685-4767

7.8 Attorney's Fees. If any dispute shall arise under this Agreement, the
prevailing party shall be entitled to its reasonable attorneys' fees and costs
of litigation from the other party.

7.9 No License. This Agreement does not grant Company a license to UW
Technology, UW Patent Rights or Technical Information.

7.10 Use of Names, Trade Names and Trademarks. Nothing in this Agreement confers
the right upon a party to use the trade name, trademark, or name of the other
party in any advertising, publicity or other promotional activities, unless the
express, written permission of the other party has been obtained. The use of the
name "University of Washington," or any contraction, abbreviation, or simulation
thereof, by Company is expressly prohibited without prior written approval.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed and delivered as of the Effective Date.

Company:

By: /s/ Chalom Sayada
    ------------------------------
    Name: Chalom Sayada, M.D, Ph.D
    Title: CEO
    Date: June 13th, 2002

University of Washington:

By: /s/ Anthony Claiborne
    ------------------------------
    Name: Anthony Claiborne
    Title: Director OTL
    Date: June 17, 2002

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

                                    EXHIBIT A

                                DEVELOPMENT PLAN

A Development Plan of the scope outlined below shall be submitted to the
University of Washington ("University") within thirty (30) days of the execution
of this Agreement. In general, the Development Plan should provide the
University with a summary overview of the activities that Company believes are
necessary to bring products based on either UW Technology or UW Patent Rights to
the marketplace.

Development Program

Development Activities to be Undertaken
(please break activities into sub-units where appropriate with the anticipated
date of completion of major milestones.)

Estimated Total Development Time

Governmental Approval (if applicable)

Types of submissions required

Government Agency (e.g. FDA, EPA, etc)

Proposed Market Research

Competitive Information

Potential Competitors

Potential Competitive Devices/Compositions

Known Competitor's plans, developments, technical achievements

D. Perceived Advantage Over Competitors

Anticipated Date of Product Launch

Total Length: approximately 2-3 pages.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                                                UW-ActiveBiotics
                                                              OTL#1169-1291129DL
                                                                       6/13/2002

<Page>

                                    EXHIBIT B

              AGREEMENT BETWEEN UNIVERSITY OF WASHINGTON AND A SHOR

                           COMMERCIALIZATION AGREEMENT

This Commercialization Agreement ("Commercialization Agreement") is entered into
on 5-13-03 ("Effective Date") by and between the University of Washington, a
public institution of higher education and an agency of the state of Washington,
acting through its Office of Technology Licensing ("OTL"), with administrative
offices at 1107 NE 45th Street, Suite 200, Seattle, WA 98105, ("University"),
and Dr. Allan Shor, having residency at 170 Hazelwood, 7 George Avenue,
Glensan, 2192 ("SHOR") (collectively the "Parties").

1.   BACKGROUND

1.1 SHOR conceived of certain technology relating to the detection of bacteria
in the cornoratry artery atheroma plaque and South African patent applications
were filed in respect of this technology by SHOR (SA 91/4565 and SA 92/3699).
SHOR made the technology available to University for further research and
development and, together with Drs. Kuo, Patton, Grayston and Campbell
("Developers"), the technology was developed, culminating in the filing of a
patent application, entitled "Detection of Bacteria in Cornatory Artery Atheroma
Plaque", which was subsequently granted as US 5,424,187 ("Invention"), and as
described in University docket 1168-1291129DL.

1.2 The Inventions were made in the course of research supported by the National
Cancer Institute (Grant#: NIH AI21885). Pursuant to 37 CFR Section 401, the
United States Government shall have rights to the Inventions by virtue of
funding provided to Drs. Kuo, Patton, Grayston, and Campbell as described above.

1.3 University and SHOR entered into an Inter Institutional Agreement on May 15,
1996 ("Management Agreement"), attached hereto as Exhibit 1, for the Invention
and the technology described in University docket 1168-1291129DL;

1.4 Subsequently, two divisional patent applications were filed, with SHOR and
University recorded as assignees. However, University declined any interest in
pursuing the divisional applications to grant. SHOR prosecuted these
applications at his own cost and they were subsequently granted as US 5,830,874
and US 6,043,225. University offered its undivided rights and interest in the
patents US 5,830,874 and US 6,043,225 back to the National Institute of Health
("NIH").

1.5 University, with the assistance of Developers, petitioned the NIH for the
return of these rights to University. NIH returned these rights to University in
May 2002.

1.6 The Parties now wish to terminate the Management Agreement and thereby
assign the rights acquired by University in the Management Agreement in and to
US 5,424,187 back to SHOR.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        1

<Page>

1.7 The Parties further wish to replace in its entirety, the Management
Agreement with this Commercialization Agreement.

1.8 In addition University and SHOR desire that their respective undivided
interests in the said Invention(s) be administered by University.

1.9 To give effect to this intention, SHOR further desires to license his
undivided interest in the Patent Rights to University on an exclusive basis.

Now Therefore, in consideration of the mutual promises set forth herein, and
other good and valuable consideration, the receipt and sufficiency of which is
hereby expressly acknowledged, the Parties hereto, intending to be legally
bound, agree as follows:

2.   DEFINITIONS

2.1 All capitalized terms used in this Commercialization Agreement have the
respective meanings ascribed to them in this Commercialization Agreement and,
unless indicated otherwise, are intended to include all derivative forms of the
terms.

2.2 "Confidential Information" means information that is/are clearly marked
"Confidential Information" or if transmitted orally, that is reduced to writing
within thirty (30) days and clearly marked "Confidential Information."
Confidential Information shall include, without limitation, Invention and
license agreements and business information related to Invention(s) exchanged
between Parties. Notwithstanding the foregoing, the receiving party shall have
no obligation of confidentiality relating to:

     2.2.1 any information of the disclosing party that is required to be
     disclosed by judicial or legislative action or government regulation;

     2.2.2 any information that is or becomes part of the public domain through
     no fault of the receiving party;

     2.2.3 any information that is known to the receiving party prior to the
     disclosure by the disclosing party, as evidenced by documentation;

     2.2.4 any information that is publicly released as authorized under this
     Commercialization Agreement by the disclosing party, its employees or
     agents;

     2.2.5 any information that is subsequently obtained by the receiving party
     from a duly authorized third party; or

     2.2.6 any information that is independently developed by the receiving
     party without any breach of this Commercialization Agreement as evidenced
     by documentation.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        2

<Page>

2.3  "Expenses" mean:

     2.3.1 all reasonable and actual out-of-pocket costs incurred by SHOR and
     University, for the preparation, filing, prosecution and maintenance of
     patent applications, including, without limitation, interferences,
     oppositions, and reexaminations, and maintenance and defense of patents and
     litigation (except those litigation costs covered by Article 9), and the
     maintenance of resulting patents;

     2.3.2 all reasonable and actual out-of-pocket legal costs incurred by SHOR
     and University for negotiating and managing assignments, waivers, licenses;

     2.3.3 any other reasonable direct cost incurred by SHOR and University and
     reasonably associated with obtaining and maintaining patent or other legal
     protection for the Inventions, or negotiating and managing assignments,
     waivers, licenses and other contracts associated with acquiring and
     transferring the Inventions; and

     2.3.4 Expenses includes all costs accrued after the Effective Date by
     University and/or SHOR for the filing, prosecution and maintenance of the
     Patent Rights.

     2.3.5 Costs 2.3.1, 2.3.2 and 2.3.3 shall be exclusive of any salaries,
     administrative, management fees related to the invention paid to a third
     party technology firm or other indirect costs.

2.4 "Invention" shall mean the technology as developed by SHOR and Dr. Kuo and
as recorded in University docket 1168-1291129DL.

2.5 "Inventors" shall mean Dr. Kuo, who was an employee of University at the
time of development the Invention and SHOR.

2.6 "Net Revenues" shall mean gross proceeds including equity and other cash or
non-cash considerations received by University from the licensing of said
Invention(s) pursuant to this Commercialization Agreement, less:

     2.6.1 [***] of such proceeds for the management of the technologies;

     2.6.2 Pro rata reimbursement of unreimbursed Expenses as defined above and
     including all costs accrued prior to the Effective Date by University and
     SHOR for the filing, prosecution and maintenance of the Patent Rights.

2.7 "Patent Rights" shall mean any and all matter claimed in or disclosed by
U.S. Patents listed below, including all patents, reissues, divisionals,
continuations, reexaminations, substitutions and extensions thereof, subject
matter claimed in any continuation-in-part on which claims issuing obtain the
benefit of a priority date of any of the foregoing applications, and all
corresponding foreign patent applications, extensions, supplemental protection
certificates and patents corresponding thereto issued during the terms of this
Commercialization Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        3

<Page>

Issued patents as of the Effective Date are:

------------------------------------------------------------------------------
United States Patent Number:          US6,043,225
------------------------------------------------------------------------------
Title:                                Diagnosis and Treatment of Arterial
                                      Chlamydial Granuloma
------------------------------------------------------------------------------
Application Date:                     3/28/2000
------------------------------------------------------------------------------
Assignee:                             University of Washington and Allan Shor
------------------------------------------------------------------------------

------------------------------------------------------------------------------
United States Patent Number:          US5,830,874
------------------------------------------------------------------------------
Title:                                Diagnosis and Treatment of Arterial
                                      Chlamydial Granuloma
------------------------------------------------------------------------------
Application Date:                     11/3/1998
------------------------------------------------------------------------------
Assignee:                             University of Washington and Allan Shor
------------------------------------------------------------------------------

------------------------------------------------------------------------------
United States Patent Number:          US5,424,187
------------------------------------------------------------------------------
Title:                                Diagnosis and Treatment of Arterial
                                      Chlamydial Granuloma
------------------------------------------------------------------------------
Application Date:                     6/13/1995
------------------------------------------------------------------------------
Assignee:                             University of Washington and Allan Shor
------------------------------------------------------------------------------

2.9 "Royalties" mean proceeds received from separate licensing arrangements
for Inventions entered into after either party has terminated this
Commercialization Agreement pursuant to Article 14.

3.   TERMINATION OF MANAGEMENT AGREEMENT AND ASSIGNMENT BACK TO SHOR

3.1 By entering into this Commercialization Agreement, the Parties hereby
agree to terminate the Management Agreement and replace it with this
Commercialization Agreement as of the Effective Date;

3.2 University hereby assigns back to SHOR all the patent rights acquired by
University in and to US 5,424,187 as provided in the Management Agreement.

4.   LICENSE TO UNIVERSITY

     SHOR hereby grants to University an exclusive license to use his
undivided interest in the Patent Rights for the purpose of commercializing
the Inventions.

5.   PATENT PROSECUTION AND PROTECTION

5.1 University shall maintain and otherwise protect the Patent Rights and
shall keep SHOR apprised of the status of the Patent Rights. University shall
be responsible for all Expenses

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                         4

<Page>

associated with the Patent Rights incurred after the Effective Date of this
Commercialization Agreement.

5.2 University agrees that all actions regarding Patent Rights require the
written approval of SHOR being the co-owner of the Patent Rights, which approval
will not be unreasonably withheld.

5.3 University agrees to copy SHOR on all correspondence between University and
patent counsel regarding Patent Rights and to forward to University any
decisions regarding Patent Rights. University will notify the SHOR of all patent
management matters within fifteen (15) business days of University's receipt of
such notifications.

5.4 University acknowledges and agrees that it will confer in good faith with
SHOR regarding any decisions regarding patent prosecution or maintenance.

5.5 University agrees that all actions regarding Patent Rights require the
written approval of SHOR, which will not be unreasonably withheld. SHOR will
submit to University such written approval within ten (10) business days after
receiving University's notification of patent management matters.

6.   LICENSING: DISTRIBUTION OF NET REVENUES

6.1 University shall have sole responsibility to seek licensee(s) and execute
licenses for the commercial development of said Inventions and the Patent
Rights, and shall administer the Inventions and the Patent Rights for the mutual
benefit of the parties and in the best public interest. SHOR shall have the
opportunity to approve all license agreements prior to final execution, which
approval shall not be unreasonably withheld or delayed and SHOR will submit to
University any comments within ten (10) business days after receiving the
agreements, and University will promptly respond to SHOR's comments. If no
comments are received within the ten (10) business days time period, approval of
the proposed license agreement will be implied, and University shall proceed
with execution of the license agreement.

6.2 University agrees to confer with SHOR regarding licensing strategies and
milestones in any negotiations concerning potential licensing of Patent Rights,
and to seek from a licensee reimbursement of all Expenses associate with Patent
Rights including costs accrued prior to the Effective Date of this
Commercialization Agreement.

6.3 University shall provide SHOR copies of all licenses conveying rights in
respect of the Patent Rights.

6.4 University agrees to consider in good faith any potential licensees that
SHOR may suggest or recommend.

6.5 University shall not assign the licenses to the Patent Rights to any third
party, notwithstanding any other provision of this Commercialization Agreement
or governmental consent, without the prior written consent of SHOR.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        5

<Page>

6.6 University shall make reasonable efforts to recover Expenses incurred by
both Shor and University prior to the Effective Date of this
Commercialization Agreement.

6.7 University shall distribute Net Revenues concurrently with distributions
it makes under University's patent policy, but in any case not later than six
months following the close of the preceding fiscal year, on the following
basis:

(a) [***] of the Net Revenues to University; and

(b) [***] of the Net Revenues to SHOR.

6.8 In the event of any litigation, actual or imminent, or any other action
to protect the Patent Rights, University may withhold all distribution and
impound Net Revenues and/or Royalties until resolution of the matter,
provided that University shall not withhold in total a greater amount
received by it than can reasonably be expected to compensate University for
its legal costs and damages arising out of such action.

6.9 SHOR agrees that any licensing of such rights is subject to any
and all rights of the U.S. government under Bayh Dole (35 USC 200 et seq. and
37 CFR S. 401 et seq.) arising from federal funding of the Inventors' research
which led to the creation or discovery of the Inventions.

7.    CONFIDENTIALITY

7.1 COMMERCIALIZATION AGREEMENT. Beginning on the Effective Date and
continuing throughout the term of this Commercialization Agreement and
thereafter for a period of Five (5) Years, neither party shall at any time,
without the express prior written consent of the other, disclose or otherwise
make known or available to any third party, any Confidential Information of
the other party. The receiving party shall utilize reasonable procedures to
safeguard the Confidential Information of the disclosing party, including
releasing such Confidential Information only on a "need-to-know" basis.

7.2 PUBLIC DISCLOSURE ACT. The University of Washington is a governmental
agency of the state of Washington and is subject to the Washington Public
Records Act, RCW 42.17 et seq., and no obligation assumed by University under
this Commercialization Agreement shall be deemed to be inconsistent with
University's obligations defined under RCW 42.17. In the event University
receives a request for public records under the Public Records Act for
documents containing Confidential Information, and if University concludes
that the documents are not otherwise exempt from public disclosure,
University will provide SHOR notice of the request before releasing such
documents. The responsibility for protecting the Confidential Information
shall reside exclusively with SHOR utilizing the procedures described in RCW
42.17.330.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                          6

<Page>

8.   RECORDS AND REPORTS

     University shall keep complete true and accurate accounts of all Expenses
and of all proceeds received by it from each licensee of the Inventions and/or
Patent Rights, and shall permit SHOR to allow a certified public accounting
firm, reasonably acceptable to University, to examine University's books and
records in order to verify the accuracy of any reports or payments due or owing
under this Commercialization Agreement.

9.   PATENT INFRINGEMENT

9.1 If SHOR or University shall learn of the substantial infringement of the
Patent Rights, the party who learned of the infringement shall promptly call the
other party's attention thereto in writing and shall provide the other party
with evidence of such infringement. University, in cooperation with SHOR, shall
use its reasonable best efforts to terminate such infringement without
litigation. If the efforts of the parties are not successful in abating the
infringement within ninety (90) days after the infringer has been formally
notified of the infringement by University after consulting with SHOR,
University shall have the right to:

     9.1.1 Permit its licensee(s) to bring suit on its own account;

     9.1.2 Commence a patent infringement suit on it own account after giving
     SHOR the opportunity to participate in the suit;

     9.1.3 Join with SHOR in such suit;

     9.1.4 Join with SHOR and any licensee in such suit; or

     9.1.5 Refuse to participate in such suit, and University shall give written
     notice to SHOR within thirty (30) days after such ninety (90)-day period of
     its election.

9.2 The parties agree that if one party to this Commercialization Agreement
brings a patent infringement action pursuant to Paragraph 8.1, then:

     9.2.1 only the party bringing the action shall be entitled to whatever
     damages may he recovered in such action;

     9.2.2 the party bringing the action, and that party alone, shall bear all
     costs and expenses associated with the action; and

     9.2.3 the party bringing the action shall indemnify and hold harmless the
     non-participating party from all costs, expenses, claims, causes of
     action, and damages arising from or in any way related to such action.

9.3 If the parties jointly prosecute a patent infringement action, then the
action shall be at the joint expense of the parties (in shares to be mutually
agreed upon) and all recoveries shall be shared jointly by them in direct
proportion to the share of expenses paid by each party.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        7

<Page>

9.4 Each party agrees to cooperate with the other in litigation proceedings
instituted hereunder but at the expense of the party on account of whom suit is
brought if brought solely for one party's account. Such litigation (including
the settlement thereof) shall be controlled by the party bringing the suit,
except that University shall control the suit if brought jointly, unless
University joins only as nominal party plaintiff. SHOR may be represented at his
expense by counsel of his choice in any suit brought solely by SHOR.

9.5 If the parties agree that SHOR shall commence suit on his own behalf or join
with University or any of its licensees in any legal action pursuant to this
Article 9 while SHOR maintains title to any patents contemplated by this
Commercialization Agreement, SHOR shall execute whatever papers are necessary to
permit such suit.

10.  GOVERNING LAWS AND VENUE

Choice of Law/Venue. The Parties agree this Commercialization Agreement shall be
governed by and interpreted in accordance with the laws of the State of
Washington, regardless of its choice of law provisions. The Parties further
agree that any claim related in any manner to the Commercialization Agreement
shall be instituted and commenced in, and venue shall be, either King or
Thurston County, Washington or the United Stated District Court for the Western
District of Washington.

11.  NOTICES AND PAYMENTS

     Any notice and/or payment required or permitted to be given to the parties
hereto shall be deemed to have been properly given if delivered, in writing, in
person or mailed by first-class certified mail to the following addresses, or
such other addresses as may designated in writing by the parties from time to
time during the term of this Commercialization Agreement:

To University:   Office of Technology Licensing
                 University of Washington
                 1107 NE 45th St, Suite 200
                 Seattle, WA 98105-4631
                 Attention: Health Sciences Manager

To SHOR:         Allan Shor
                 170 Hazelwood
                 7 George Avenue
                 Glensan
                 2192

                 PO Box 29111
                 Sandringham 2131
                 South Africa

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        8

<Page>

12.  WAIVER

     It is agreed that no waiver by either party hereto of any breach or
default of any of the covenants or agreements herein set forth shall be
deemed a waiver as to any subsequent and/or similar breach or default.

13.  ASSIGNABILITY

     This Commercialization Agreement may not be assigned by either party
without the prior written consent of the other party and consent of the
government, to the extent consent of the latter may be required.

14.  LIFE OF AGREEMENT

     This Commercialization Agreement shall be in full force and effect from
the Effective Date and shall remain in effect for the life of the last to
expire of patents contemplated by this Commercialization Agreement, unless
otherwise terminated by operation of law or by acts of the parties in
accordance with the terms of this Commercialization Agreement or Sponsor's
requirements.

15.  TERMINATION

15.1 Either party may terminate this Commercialization Agreement
("Terminating Party") upon sixty (60) days written notice to the other party
("Non-terminating Party") but not less than sixty (60) days before any
pending Patent Office actions necessary to preserve patent rights.

15.2 The termination of this Commercialization Agreement will not affect any
of the rights granted to any licensee prior to termination.

15.3 The Non-terminating party may elect to request assignment of any or all
licenses issued by Terminating Party and will administer existing licenses
without accounting to the Terminating Party, except that Non-terminating
Party shall:

(a) Retain [***] of future gross proceeds for administrative overhead
provided for in Paragraph 2.6 hereof; and

(b) Distribute to Terminating Party in accordance with Paragraph 2.6 Net
Revenues accruing under continuing licenses negotiated prior to termination,
but such distribution shall be made in accordance with Non-terminating
Party's policy.

15.4 Non-terminating Party shall make its election and shall advise
Terminating Party in writing within thirty (30) days after receipt of notice
of termination, and Terminating Party shall

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                        9

<Page>

thereupon convey to Non-terminating Party assignment of the licenses and shall
do all things necessary to transfer all files related to such licenses to
Non-terminating Party or its designee.

15.5 After termination, each party will have the right to license their
respective rights in the Inventions without accounting to the other party,
subject to any rights previously granted in license agreements entered into
prior to termination.

15.6 Upon termination of this Commercialization Agreement by either party
(Terminating Party), the Terminating Party will still be responsible for its
portion of Recoverable Costs incurred prior to termination.

16.  SEVERABILITY

If any provision of this Commercialization Agreement or the application thereof
to any person or circumstance shall be invalid, illegal or unenforceable to any
extent, the remainder of this Commercialization Agreement and the application
thereof shall not be affected and shall be enforceable to the fullest extent
permitted by law.

17.  HEIRS, SUCCESSORS, AND ASSIGNS

Each of the terms, provisions and agreements herein contained shall be binding
upon and inure to the benefit of the parties hereto and, to the extent permitted
by this Commercialization Agreement, their respective heirs, legal
representatives, successors and assigns.

18.  AMENDMENTS

This Commercialization Agreement may not be amended except by the unanimous
written agreement of both of the parties.

19.  COMPLETE AGREEMENT

It is understood and agreed between SHOR and University that this
Commercialization Agreement constitutes the entire agreement, both written and
oral, between the parties, and that all prior agreements respecting the subject
matter hereof, either written or oral, expressed or implied, shall be abrogated,
cancelled, and are null and void and of no effect.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                       10

<Page>

In WITNESS WHEREOF, the parties hereto have executed this Commercialization
Agreement in duplicate originals by their duly authorized officers or
representatives.

UNIVERSITY OF WASHINGTON                   DR. ALLAN SHOR

By /s/ Anthony Claiborne                   By /s/ Allan Shor
   -------------------------------------      ----------------------------------
Date 5-13-2002                             Date 5-20-2002

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED

                                       11

<Page>

                         [UNIVERSITY OF WASHINGTON LOGO]

                            UNIVERSITY OF WASHINGT0N

                         OFFICE OF TECHNOLOGY LICENSING

June 18, 2002                                         SENT VIA UPS INTERNATIONAL

Dr. Allan Shor
170 Hazelwood
7 George Avenue
Glensan
2192 South Africa

Re: Commercialization Agreement between University of Washington
    and Dr. Allan Shor
    UW OTL 1168-1291129-I2167CA
    Relating to Issued US Patents: 6,043,225; 5,830,874 and 5,424,187

Dear Allan,

It has come to our attention that the effective date for the above referenced
Commercialization Agreement was incorrectly listed as May 13, 2003 on the
originals sent to you for execution.

It was our mutual intention that the effective date for the Commercialization
Agreement be May 13, 2002. Please attach this letter to your copy of the
Agreement to confirm our intention. If you could also draft a similar letter and
return it to us confirming your intention that the Agreement's effective date is
May 13, 2002 it would be most helpful.

We are grateful for Michael Pettit's help and advice in this matter. Please do
not hesitate to contact us if you require further information.

Sincerely,

/s/ Annette Kleiser
-------------------------------------
Annette Kleiser, PhD
Manager of Technology Licensing
Office of Technology Licensing

CC: Michael Pettit, Spoor & Fisher Johannesburg

AK/1gm

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

<Page>

                                   EXHIBIT 1.2

                                   Affiliates

As of the Effective Date, there are no Affiliates.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

<Page>

                                  EXHIBIT 1.17

                     Issued patents as of the Effective Date

United States Patent Number:   6,043,225

Title:                         Diagnosis and Treatment of Arterial Chlamydial
                               Granuloma

Application Date:              3/28/2000

Assignee:                      University of Washington and Allan Shor*

United States Patent Number:   5,830,874

Title:                         Diagnosis and Treatment of Arterial Chlamydial
                               Granuloma

Application Date:              11/3/1998

Assignee:                      University of Washington and Allan Shor*

United States Patent Number:   5,424,187

Title:                         Diagnosis and Treatment of Arterial Chlamydial
                               Granuloma

Application Date:              6/13/1995

Assignee:                      University of Washington and Allan Shor*

*    Exclusively controlled by University of Washington under separate agreement
     with Allan Shor

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]